data/dev.conll

Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
22 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sana. B-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
aumento I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
volumen I-PRESENT_ILLNESS
cérvico-parotídeo I-PRESENT_ILLNESS
derecho I-PRESENT_ILLNESS
sensible, I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
refractario I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
antiinflamatorios. I-PRESENT_ILLNESS
Fue B-TREATMENT
interpretado I-TREATMENT
como I-TREATMENT
síndrome I-TREATMENT
de I-TREATMENT
mononucleosis I-TREATMENT
infecciosa I-TREATMENT
y I-TREATMENT
por I-TREATMENT
su I-TREATMENT
persistencia I-TREATMENT
se I-TREATMENT
le I-TREATMENT
indicó I-TREATMENT
empíricamente I-TREATMENT
amoxicilina-ácido I-TREATMENT
clavulánico I-TREATMENT
sin I-TREATMENT
mejoría I-TREATMENT
clínica. I-TREATMENT
Finalmente, I-TREATMENT
le I-TREATMENT
indicaron I-TREATMENT
glucocorticoides I-TREATMENT
con B-EVOLUTION
resolución I-EVOLUTION
completa I-EVOLUTION
del I-EVOLUTION
cuadro. I-EVOLUTION
<EOS> I-EVOLUTION
Dos I-EVOLUTION
meses I-EVOLUTION
después I-EVOLUTION
consultó I-EVOLUTION
nuevamente I-EVOLUTION
por I-EVOLUTION
fiebre I-EVOLUTION
asociado I-EVOLUTION
a I-EVOLUTION
múltiples I-EVOLUTION
adenopatías I-EVOLUTION
submandibulares I-EVOLUTION
sensibles I-EVOLUTION
e I-EVOLUTION
induradas, I-EVOLUTION
con I-EVOLUTION
aumento I-EVOLUTION
de I-EVOLUTION
volumen I-EVOLUTION
parotídeo I-EVOLUTION
ipsilateral. I-EVOLUTION
Presentaba B-EXPLORATION
PCR I-EXPLORATION
de I-EXPLORATION
41 I-EXPLORATION
mg/L I-EXPLORATION
y I-EXPLORATION
hemograma I-EXPLORATION
con I-EXPLORATION
neutro I-EXPLORATION
filia I-EXPLORATION
relativa. I-EXPLORATION
Las I-EXPLORATION
pruebas I-EXPLORATION
hepáticas I-EXPLORATION
y I-EXPLORATION
LDH I-EXPLORATION
estaban I-EXPLORATION
en I-EXPLORATION
rangos I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
solicitó I-EXPLORATION
TAC I-EXPLORATION
cervical I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
volumen I-EXPLORATION
parotídeo I-EXPLORATION
y I-EXPLORATION
de I-EXPLORATION
grupos I-EXPLORATION
ganglionares I-EXPLORATION
cervicales I-EXPLORATION
bilaterales, I-EXPLORATION
ambos I-EXPLORATION
de I-EXPLORATION
predominio I-EXPLORATION
derecho. I-EXPLORATION
Además I-EXPLORATION
se I-EXPLORATION
informó I-EXPLORATION
un I-EXPLORATION
probable I-EXPLORATION
flegmón I-EXPLORATION
cervical. I-EXPLORATION
Se I-EXPLORATION
reiniciaron I-EXPLORATION
los I-EXPLORATION
antibióticos I-EXPLORATION
(ceftriaxona I-EXPLORATION
más I-EXPLORATION
clindamicina) I-EXPLORATION
sin I-EXPLORATION
respuesta. I-EXPLORATION
Dada B-TREATMENT
la I-TREATMENT
persistencia I-TREATMENT
del I-TREATMENT
cuadro, I-TREATMENT
se I-TREATMENT
escaló I-TREATMENT
a I-TREATMENT
esquema I-TREATMENT
antibiótico I-TREATMENT
de I-TREATMENT
segunda I-TREATMENT
línea I-TREATMENT
(vancomicina I-TREATMENT
más I-TREATMENT
levofloxacino) I-TREATMENT
y B-EXPLORATION
se I-EXPLORATION
amplió I-EXPLORATION
estudio I-EXPLORATION
con I-EXPLORATION
TAC I-EXPLORATION
de I-EXPLORATION
tórax-abdomen-pelvis I-EXPLORATION
que I-EXPLORATION
informó I-EXPLORATION
linfonodos I-EXPLORATION
precarinales I-EXPLORATION
de I-EXPLORATION
6 I-EXPLORATION
mm, I-EXPLORATION
sin I-EXPLORATION
otros I-EXPLORATION
hallazgos. I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
inmunológico I-EXPLORATION
con I-EXPLORATION
ANA I-EXPLORATION
e I-EXPLORATION
infeccioso I-EXPLORATION
para I-EXPLORATION
VEB, I-EXPLORATION
CMV, I-EXPLORATION
VIH, I-EXPLORATION
sífilis, I-EXPLORATION
Toxoplasma I-EXPLORATION
gondii I-EXPLORATION
y I-EXPLORATION
Bartonella I-EXPLORATION
hensenlae I-EXPLORATION
fueron I-EXPLORATION
negativos. I-EXPLORATION
Finalmente, I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
biopsia I-EXPLORATION
de I-EXPLORATION
ganglio I-EXPLORATION
cervical I-EXPLORATION
que I-EXPLORATION
reveló I-EXPLORATION
hallazgos I-EXPLORATION
compatibles I-EXPLORATION
con I-EXPLORATION
linfadenitis I-EXPLORATION
necrotizante I-EXPLORATION
histiocitaria. I-EXPLORATION
Se B-TREATMENT
suspendieron I-TREATMENT
los I-TREATMENT
antibióticos I-TREATMENT
y I-TREATMENT
se I-TREATMENT
indicó I-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
prednisona I-TREATMENT
30 I-TREATMENT
mg I-TREATMENT
al I-TREATMENT
día I-TREATMENT
con I-TREATMENT
disminución I-TREATMENT
progresiva I-TREATMENT
de I-TREATMENT
las I-TREATMENT
dosis I-TREATMENT
a I-TREATMENT
partir I-TREATMENT
de I-TREATMENT
la I-TREATMENT
segunda I-TREATMENT
semana, I-TREATMENT
completando I-TREATMENT
1 I-TREATMENT
mes I-TREATMENT
de I-TREATMENT
tratamiento. I-TREATMENT
La B-EVOLUTION
fiebre I-EVOLUTION
cedió I-EVOLUTION
a I-EVOLUTION
las I-EVOLUTION
24 I-EVOLUTION
h I-EVOLUTION
tras I-EVOLUTION
el I-EVOLUTION
inicio I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
terapia I-EVOLUTION
y I-EVOLUTION
no I-EVOLUTION
ha I-EVOLUTION
presentado I-EVOLUTION
recurrencias I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
6 I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
seguimiento. I-EVOLUTION
<EOS> I-EVOLUTION

Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
60 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sin B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
mórbidos, I-PAST_MEDICAL_HISTORY
a B-PRESENT_ILLNESS
quien I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
tomografía I-PRESENT_ILLNESS
computada I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
abdomen I-PRESENT_ILLNESS
efectuada I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
abdominal, I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
le I-PRESENT_ILLNESS
encontró I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
carcinoma I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
2 I-PRESENT_ILLNESS
cm I-PRESENT_ILLNESS
localizado I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
cabeza I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
páncreas. I-PRESENT_ILLNESS
Fue B-TREATMENT
sometido I-TREATMENT
a I-TREATMENT
una I-TREATMENT
operación I-TREATMENT
de I-TREATMENT
Whipple. I-TREATMENT
Había I-TREATMENT
2 I-TREATMENT
adenopatías I-TREATMENT
regionales I-TREATMENT
con I-TREATMENT
metástasis I-TREATMENT
de I-TREATMENT
carcinoma I-TREATMENT
y I-TREATMENT
no I-TREATMENT
existía I-TREATMENT
diseminación I-TREATMENT
a I-TREATMENT
distancia. I-TREATMENT
Tres I-TREATMENT
meses I-TREATMENT
después I-TREATMENT
de I-TREATMENT
la I-TREATMENT
operación I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
quimioterapia I-TREATMENT
con I-TREATMENT
GEM. I-TREATMENT
Después B-EVOLUTION
de I-EVOLUTION
recibir I-EVOLUTION
11 I-EVOLUTION
dosis I-EVOLUTION
de I-EVOLUTION
GEM, I-EVOLUTION
transcurridos I-EVOLUTION
4 I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
su I-EVOLUTION
inicio I-EVOLUTION
y I-EVOLUTION
habiendo I-EVOLUTION
recibido I-EVOLUTION
una I-EVOLUTION
dosis I-EVOLUTION
total I-EVOLUTION
acumulada I-EVOLUTION
de I-EVOLUTION
16.400 I-EVOLUTION
mg I-EVOLUTION
(9.318 I-EVOLUTION
mg/m2), I-EVOLUTION
presentó I-EVOLUTION
edema I-EVOLUTION
palpebral I-EVOLUTION
y I-EVOLUTION
de I-EVOLUTION
tobillos I-EVOLUTION
e I-EVOLUTION
hipertensión I-EVOLUTION
arterial I-EVOLUTION
de I-EVOLUTION
hasta I-EVOLUTION
160/110 I-EVOLUTION
mmHg. I-EVOLUTION
Los B-EXPLORATION
exámenes I-EXPLORATION
de I-EXPLORATION
laboratorio I-EXPLORATION
mostraron I-EXPLORATION
hematuria I-EXPLORATION
microscópica I-EXPLORATION
(26-50 I-EXPLORATION
hematíes I-EXPLORATION
por I-EXPLORATION
campo), I-EXPLORATION
proteinuria I-EXPLORATION
(1.740 I-EXPLORATION
mg/24 I-EXPLORATION
h), I-EXPLORATION
cilindruria I-EXPLORATION
granulosa, I-EXPLORATION
ascenso I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
creatinina I-EXPLORATION
sérica I-EXPLORATION
hasta I-EXPLORATION
un I-EXPLORATION
máximo I-EXPLORATION
de I-EXPLORATION
2, I-EXPLORATION
0 I-EXPLORATION
mg/dL I-EXPLORATION
con I-EXPLORATION
caída I-EXPLORATION
del I-EXPLORATION
clearance I-EXPLORATION
de I-EXPLORATION
creatinina I-EXPLORATION
a I-EXPLORATION
52 I-EXPLORATION
ml/min/1, I-EXPLORATION
73 I-EXPLORATION
m2 I-EXPLORATION
(medido) I-EXPLORATION
a I-EXPLORATION
los I-EXPLORATION
21 I-EXPLORATION
días I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
última I-EXPLORATION
dosis. I-EXPLORATION
Previo I-EXPLORATION
a I-EXPLORATION
ello I-EXPLORATION
se I-EXPLORATION
había I-EXPLORATION
observado I-EXPLORATION
anemia I-EXPLORATION
progresiva I-EXPLORATION
(hemoglobina I-EXPLORATION
6.0 I-EXPLORATION
g/dL) I-EXPLORATION
y I-EXPLORATION
trombocitopenia I-EXPLORATION
(20.000 I-EXPLORATION
mm3), I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
atribuyeron I-EXPLORATION
a I-EXPLORATION
mielodepresión I-EXPLORATION
por I-EXPLORATION
GEM. I-EXPLORATION
La I-EXPLORATION
bilirrubinemia I-EXPLORATION
total I-EXPLORATION
ascendió I-EXPLORATION
a I-EXPLORATION
1, I-EXPLORATION
79 I-EXPLORATION
mg/dL, I-EXPLORATION
la I-EXPLORATION
directa I-EXPLORATION
a I-EXPLORATION
0, I-EXPLORATION
93 I-EXPLORATION
mg/dL I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
LDH I-EXPLORATION
a I-EXPLORATION
701 I-EXPLORATION
U/L I-EXPLORATION
(VN: I-EXPLORATION
125-243), I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
interpretó I-EXPLORATION
como I-EXPLORATION
secundario I-EXPLORATION
a I-EXPLORATION
toxicidad I-EXPLORATION
hepática I-EXPLORATION
por I-EXPLORATION
GEM. I-EXPLORATION
Se B-TREATMENT
suspendió I-TREATMENT
la I-TREATMENT
administración I-TREATMENT
de I-TREATMENT
nuevas I-TREATMENT
dosis I-TREATMENT
de I-TREATMENT
GEM, I-TREATMENT
se I-TREATMENT
prescribió I-TREATMENT
furosemi-de I-TREATMENT
para I-TREATMENT
controlar I-TREATMENT
el I-TREATMENT
edema I-TREATMENT
y I-TREATMENT
olmesartán I-TREATMENT
para I-TREATMENT
el I-TREATMENT
manejo I-TREATMENT
de I-TREATMENT
la I-TREATMENT
hipertensión I-TREATMENT
arterial. I-TREATMENT
<EOS> I-TREATMENT
Estando B-EXPLORATION
el I-EXPLORATION
recuento I-EXPLORATION
de I-EXPLORATION
plaquetas I-EXPLORATION
sobre I-EXPLORATION
100.000 I-EXPLORATION
mm3 I-EXPLORATION
se I-EXPLORATION
efectuó I-EXPLORATION
una I-EXPLORATION
biopsia I-EXPLORATION
renal I-EXPLORATION
percutánea I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
hallazgos I-EXPLORATION
característicos I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
microangiopatía I-EXPLORATION
trombótica I-EXPLORATION
crónica I-EXPLORATION
activa. I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
de I-EXPLORATION
microscopía I-EXPLORATION
óptica I-EXPLORATION
reveló I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
glomérulos I-EXPLORATION
con I-EXPLORATION
numerosos I-EXPLORATION
dobles I-EXPLORATION
contornos I-EXPLORATION
en I-EXPLORATION
sus I-EXPLORATION
asas I-EXPLORATION
capilares I-EXPLORATION
y I-EXPLORATION
arteriolas, I-EXPLORATION
con I-EXPLORATION
intensa I-EXPLORATION
disminución I-EXPLORATION
de I-EXPLORATION
su I-EXPLORATION
lumen, I-EXPLORATION
hiperplasia I-EXPLORATION
concéntrica I-EXPLORATION
de I-EXPLORATION
miocélulas I-EXPLORATION
y I-EXPLORATION
depósito I-EXPLORATION
hialino I-EXPLORATION
mural I-EXPLORATION
sugerente I-EXPLORATION
de I-EXPLORATION
material I-EXPLORATION
microtrombótico I-EXPLORATION
incorporado I-EXPLORATION
en I-EXPLORATION
su I-EXPLORATION
endotelio I-EXPLORATION
y I-EXPLORATION
pared. I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
de I-EXPLORATION
inmunofluorescencia I-EXPLORATION
no I-EXPLORATION
mostró I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
complejos I-EXPLORATION
inmunes I-EXPLORATION
en I-EXPLORATION
los I-EXPLORATION
glomérulos. I-EXPLORATION
La I-EXPLORATION
microscopía I-EXPLORATION
electrónica I-EXPLORATION
confirmó I-EXPLORATION
las I-EXPLORATION
alteraciones I-EXPLORATION
glomerulares I-EXPLORATION
encontradas I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
microscopía I-EXPLORATION
óptica; I-EXPLORATION
en I-EXPLORATION
especial, I-EXPLORATION
se I-EXPLORATION
demostró I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
múltiples I-EXPLORATION
dobles I-EXPLORATION
contornos I-EXPLORATION
con I-EXPLORATION
interposición I-EXPLORATION
celular I-EXPLORATION
y I-EXPLORATION
expansión I-EXPLORATION
acentuada I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
lámina I-EXPLORATION
rara I-EXPLORATION
interna I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
membrana I-EXPLORATION
basal I-EXPLORATION
por I-EXPLORATION
material I-EXPLORATION
electrón-lúcido I-EXPLORATION
y I-EXPLORATION
detritus I-EXPLORATION
subendotelial. I-EXPLORATION
Todas I-EXPLORATION
estas I-EXPLORATION
alteraciones I-EXPLORATION
se I-EXPLORATION
encontraron I-EXPLORATION
en I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
depósitos I-EXPLORATION
densos I-EXPLORATION
de I-EXPLORATION
tipo I-EXPLORATION
complejo I-EXPLORATION
inmune. I-EXPLORATION
La I-EXPLORATION
lesión I-EXPLORATION
pedicelar I-EXPLORATION
fue I-EXPLORATION
moderada. I-EXPLORATION
<EOS> I-EXPLORATION
La B-EVOLUTION
suspensión I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
GEM I-EVOLUTION
se I-EVOLUTION
acompañó I-EVOLUTION
de I-EVOLUTION
una I-EVOLUTION
mejoría I-EVOLUTION
en I-EVOLUTION
la I-EVOLUTION
función I-EVOLUTION
renal I-EVOLUTION
y I-EVOLUTION
de I-EVOLUTION
los I-EVOLUTION
parámetros I-EVOLUTION
hematológicos. I-EVOLUTION
En B-EXPLORATION
el I-EXPLORATION
último I-EXPLORATION
control, I-EXPLORATION
10 I-EXPLORATION
sem I-EXPLORATION
después I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
última I-EXPLORATION
dosis I-EXPLORATION
de I-EXPLORATION
GEM, I-EXPLORATION
la I-EXPLORATION
hemoglobina I-EXPLORATION
fue I-EXPLORATION
12, I-EXPLORATION
3 I-EXPLORATION
g/dL, I-EXPLORATION
plaquetas I-EXPLORATION
147.000 I-EXPLORATION
mm3, I-EXPLORATION
leucocitos I-EXPLORATION
4.700 I-EXPLORATION
mm3, I-EXPLORATION
creatinina I-EXPLORATION
sérica I-EXPLORATION
1, I-EXPLORATION
18 I-EXPLORATION
mg/dl, I-EXPLORATION
clearance I-EXPLORATION
de I-EXPLORATION
creatinina I-EXPLORATION
85 I-EXPLORATION
ml/min/1, I-EXPLORATION
73 I-EXPLORATION
m2 I-EXPLORATION
y I-EXPLORATION
LDH I-EXPLORATION
normal. I-EXPLORATION
El B-TREATMENT
paciente I-TREATMENT
continuó I-TREATMENT
recibiendo I-TREATMENT
olmesartán I-TREATMENT
como I-TREATMENT
terapia I-TREATMENT
antihipertensiva I-TREATMENT
originada I-TREATMENT
por I-TREATMENT
el I-TREATMENT
daño I-TREATMENT
renal I-TREATMENT
por I-TREATMENT
GEM. I-TREATMENT
<EOS> I-TREATMENT
. I-TREATMENT
<EOS> I-TREATMENT

Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
46 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
infección I-PAST_MEDICAL_HISTORY
respiratoria I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
semana I-PAST_MEDICAL_HISTORY
previa, I-PAST_MEDICAL_HISTORY
luego B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
cinco I-PRESENT_ILLNESS
días I-PRESENT_ILLNESS
comenzó I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
disartria, I-PRESENT_ILLNESS
diplopía, I-PRESENT_ILLNESS
vértigo I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
ataxia. I-PRESENT_ILLNESS
Al B-EXPLORATION
examen I-EXPLORATION
se I-EXPLORATION
objetivó I-EXPLORATION
disartria, I-EXPLORATION
midriasis I-EXPLORATION
con I-EXPLORATION
reflejos I-EXPLORATION
fotomotores I-EXPLORATION
(RFM) I-EXPLORATION
disminuidos, I-EXPLORATION
paresia I-EXPLORATION
del I-EXPLORATION
recto I-EXPLORATION
superior I-EXPLORATION
izquierdo, I-EXPLORATION
nistagmus I-EXPLORATION
bihorizontal, I-EXPLORATION
ROT I-EXPLORATION
abolidos, I-EXPLORATION
dismetría I-EXPLORATION
bilateral I-EXPLORATION
y I-EXPLORATION
Romberg I-EXPLORATION
positivo. I-EXPLORATION
Se I-EXPLORATION
estudió I-EXPLORATION
con I-EXPLORATION
RM I-EXPLORATION
encéfalo I-EXPLORATION
normal. I-EXPLORATION
La I-EXPLORATION
EMG I-EXPLORATION
presentó I-EXPLORATION
alteración I-EXPLORATION
del I-EXPLORATION
reflejo I-EXPLORATION
de I-EXPLORATION
pestañeo. I-EXPLORATION
Sin I-EXPLORATION
disociación I-EXPLORATION
en I-EXPLORATION
LCR I-EXPLORATION
y I-EXPLORATION
anticuerpos I-EXPLORATION
anti-GQ1b I-EXPLORATION
positivos I-EXPLORATION
en I-EXPLORATION
suero. I-EXPLORATION
Evolucionó B-EVOLUTION
con I-EVOLUTION
sopor, I-EVOLUTION
midriasis I-EVOLUTION
arrefléctica, I-EVOLUTION
biparesia I-EVOLUTION
facial I-EVOLUTION
y I-EVOLUTION
paresia I-EVOLUTION
de I-EVOLUTION
extremidades I-EVOLUTION
superiores. I-EVOLUTION
Requirió B-TREATMENT
intubación I-TREATMENT
para I-TREATMENT
manejo I-TREATMENT
de I-TREATMENT
vía I-TREATMENT
aérea I-TREATMENT
y I-TREATMENT
monitorización I-TREATMENT
por I-TREATMENT
disautonomía. I-TREATMENT
Se I-TREATMENT
establecieron I-TREATMENT
los I-TREATMENT
diagnósticos I-TREATMENT
de I-TREATMENT
SMF, I-TREATMENT
SGB I-TREATMENT
y I-TREATMENT
EB. I-TREATMENT
Recibió I-TREATMENT
IgIV I-TREATMENT
(0, I-TREATMENT
4 I-TREATMENT
gr/kg/día I-TREATMENT
por I-TREATMENT
5 I-TREATMENT
días I-TREATMENT
consecutivos). I-TREATMENT
A B-EVOLUTION
los I-EVOLUTION
6 I-EVOLUTION
meses I-EVOLUTION
tenía I-EVOLUTION
examen I-EVOLUTION
neurológico I-EVOLUTION
normal. I-EVOLUTION
<EOS> I-EVOLUTION

Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
52 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
no B-PAST_MEDICAL_HISTORY
fumadora, I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
GPA I-PAST_MEDICAL_HISTORY
diagnosticada I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
1995. I-PAST_MEDICAL_HISTORY
Al B-PRESENT_ILLNESS
diagnóstico I-PRESENT_ILLNESS
presentó I-PRESENT_ILLNESS
compromiso I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
VAS, I-PRESENT_ILLNESS
pulmón I-PRESENT_ILLNESS
(cuya I-PRESENT_ILLNESS
biopsia I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
masa I-PRESENT_ILLNESS
pulmonar I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
videotoracoscopía I-PRESENT_ILLNESS
mostró I-PRESENT_ILLNESS
infamación I-PRESENT_ILLNESS
granulomatosa I-PRESENT_ILLNESS
necrotizante), I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
micro-hematuria I-PRESENT_ILLNESS
asociado I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
astenia, I-PRESENT_ILLNESS
pérdida I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
peso I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
fiebre, I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
lo I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
diagnosticó I-PRESENT_ILLNESS
GPA I-PRESENT_ILLNESS
generalizada. I-PRESENT_ILLNESS
Al B-EXPLORATION
diagnóstico I-EXPLORATION
la I-EXPLORATION
VSG I-EXPLORATION
fue I-EXPLORATION
de I-EXPLORATION
113 I-EXPLORATION
mm, I-EXPLORATION
el I-EXPLORATION
ANCA I-EXPLORATION
c I-EXPLORATION
positivos I-EXPLORATION
(no I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
PR3) I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
CFV I-EXPLORATION
normal. I-EXPLORATION
Recibió B-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
esteroides I-TREATMENT
y I-TREATMENT
ciclofosfamida I-TREATMENT
con I-TREATMENT
remisión I-TREATMENT
completa I-TREATMENT
de I-TREATMENT
los I-TREATMENT
síntomas, I-TREATMENT
analítica I-TREATMENT
e I-TREATMENT
imágenes. I-TREATMENT
Se I-TREATMENT
realizó I-TREATMENT
mantenimiento I-TREATMENT
con I-TREATMENT
ciclofosfamida. I-TREATMENT
<EOS> I-TREATMENT
A B-EVOLUTION
lo I-EVOLUTION
largo I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
evolución, I-EVOLUTION
presentó I-EVOLUTION
múltiples I-EVOLUTION
recaídas I-EVOLUTION
que I-EVOLUTION
respondieron I-EVOLUTION
a I-EVOLUTION
terapéutica I-EVOLUTION
específica. I-EVOLUTION
Las I-EVOLUTION
recaídas I-EVOLUTION
siempre I-EVOLUTION
fueron I-EVOLUTION
en I-EVOLUTION
VAS, I-EVOLUTION
con I-EVOLUTION
otitis, I-EVOLUTION
sinusitis I-EVOLUTION
y I-EVOLUTION
epistaxis I-EVOLUTION
recurrentes. I-EVOLUTION
Presentó I-EVOLUTION
perforación I-EVOLUTION
del I-EVOLUTION
tabique I-EVOLUTION
nasal I-EVOLUTION
y I-EVOLUTION
mielosupresión I-EVOLUTION
por I-EVOLUTION
ciclofosfamida, I-EVOLUTION
por B-TREATMENT
lo I-TREATMENT
cual I-TREATMENT
se I-TREATMENT
rotó I-TREATMENT
el I-TREATMENT
tratamiento I-TREATMENT
a I-TREATMENT
micofenolato I-TREATMENT
en I-TREATMENT
dosis I-TREATMENT
de I-TREATMENT
tres I-TREATMENT
gramos I-TREATMENT
día. I-TREATMENT
<EOS> I-TREATMENT
Al B-EVOLUTION
año I-EVOLUTION
del I-EVOLUTION
diagnóstico I-EVOLUTION
comenzó I-EVOLUTION
con I-EVOLUTION
disnea I-EVOLUTION
y I-EVOLUTION
estridor I-EVOLUTION
laríngeo. I-EVOLUTION
Se B-EXPLORATION
realizó I-EXPLORATION
EFR I-EXPLORATION
que I-EXPLORATION
evidenció I-EXPLORATION
curva I-EXPLORATION
cajón I-EXPLORATION
y I-EXPLORATION
TAC I-EXPLORATION
de I-EXPLORATION
traquea I-EXPLORATION
y I-EXPLORATION
laringe I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
ESG. I-EXPLORATION
Requirió B-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
radiofrecuencia I-TREATMENT
y I-TREATMENT
dilatación. I-TREATMENT
Durante I-TREATMENT
los I-TREATMENT
años I-TREATMENT
2003, I-TREATMENT
2005, I-TREATMENT
2006 I-TREATMENT
se I-TREATMENT
efectuaron I-TREATMENT
dilataciones, I-TREATMENT
llegando I-TREATMENT
a I-TREATMENT
realizar I-TREATMENT
traqueostomía I-TREATMENT
en I-TREATMENT
el I-TREATMENT
2008. I-TREATMENT
Falleció B-EVOLUTION
en I-EVOLUTION
el I-EVOLUTION
año I-EVOLUTION
2009 I-EVOLUTION
en I-EVOLUTION
contexto I-EVOLUTION
de I-EVOLUTION
una I-EVOLUTION
neumonía I-EVOLUTION
nosocomial. I-EVOLUTION
<EOS> I-EVOLUTION

Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
31 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
consultó I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
pérdida I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
fuerzas I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
instalación I-PRESENT_ILLNESS
rápida, I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
compromiso I-PRESENT_ILLNESS
inicial I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
miembros I-PRESENT_ILLNESS
inferiores I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
progresión I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
miembros I-PRESENT_ILLNESS
superiores I-PRESENT_ILLNESS
determinando I-PRESENT_ILLNESS
cuadriparesia I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
cefaloparesia. I-PRESENT_ILLNESS
Destacaba B-PAST_MEDICAL_HISTORY
entre I-PAST_MEDICAL_HISTORY
sus I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
ser I-PAST_MEDICAL_HISTORY
portador I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
virus I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
inmunodeficiencia I-PAST_MEDICAL_HISTORY
humana I-PAST_MEDICAL_HISTORY
(VIH) I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
etapa I-PAST_MEDICAL_HISTORY
SIDA I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
cumplimiento I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
antiretroviral. I-PAST_MEDICAL_HISTORY
Presentaba B-PRESENT_ILLNESS
diarrea I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
múltiples I-PRESENT_ILLNESS
deposiciones I-PRESENT_ILLNESS
diarias I-PRESENT_ILLNESS
durante I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
10 I-PRESENT_ILLNESS
días I-PRESENT_ILLNESS
previos I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
consulta. I-PRESENT_ILLNESS
Al B-EXPLORATION
ingreso I-EXPLORATION
se I-EXPLORATION
encontraba I-EXPLORATION
vigil, I-EXPLORATION
eupneico I-EXPLORATION
y I-EXPLORATION
apirético. I-EXPLORATION
Tenía I-EXPLORATION
aceptable I-EXPLORATION
estado I-EXPLORATION
de I-EXPLORATION
hidratación I-EXPLORATION
y I-EXPLORATION
TA I-EXPLORATION
de I-EXPLORATION
110/70 I-EXPLORATION
mmHg. I-EXPLORATION
En I-EXPLORATION
la I-EXPLORATION
valoración I-EXPLORATION
neuromuscular I-EXPLORATION
se I-EXPLORATION
objetivaba I-EXPLORATION
cuadriparesia I-EXPLORATION
con I-EXPLORATION
cefaloparesia. I-EXPLORATION
El I-EXPLORATION
K+pl I-EXPLORATION
al I-EXPLORATION
momento I-EXPLORATION
del I-EXPLORATION
ingreso I-EXPLORATION
fue I-EXPLORATION
informado I-EXPLORATION
como I-EXPLORATION
indetectable, I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
valor I-EXPLORATION
de I-EXPLORATION
K+ I-EXPLORATION
urinario I-EXPLORATION
en I-EXPLORATION
muestra I-EXPLORATION
aislada I-EXPLORATION
de I-EXPLORATION
5 I-EXPLORATION
mEq/L. I-EXPLORATION
Presentaba I-EXPLORATION
elevación I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
CK. I-EXPLORATION
Se B-TREATMENT
inició I-TREATMENT
reposición I-TREATMENT
hidroelectrolítica I-TREATMENT
con I-TREATMENT
mejoría I-TREATMENT
de I-TREATMENT
la I-TREATMENT
cuadriparesia I-TREATMENT
y I-TREATMENT
normalización I-TREATMENT
de I-TREATMENT
los I-TREATMENT
valores I-TREATMENT
de I-TREATMENT
K+pl I-TREATMENT
y I-TREATMENT
CK. I-TREATMENT
Al I-TREATMENT
igual I-TREATMENT
que I-TREATMENT
el I-TREATMENT
caso I-TREATMENT
1, I-TREATMENT
la I-TREATMENT
severa I-TREATMENT
disminución I-TREATMENT
del I-TREATMENT
potasio I-TREATMENT
plasmático I-TREATMENT
se I-TREATMENT
debió I-TREATMENT
a I-TREATMENT
una I-TREATMENT
alteración I-TREATMENT
a I-TREATMENT
nivel I-TREATMENT
del I-TREATMENT
balance I-TREATMENT
externo I-TREATMENT
por I-TREATMENT
pérdidas I-TREATMENT
de I-TREATMENT
origen I-TREATMENT
digestivo, I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
concuerda I-TREATMENT
con I-TREATMENT
el I-TREATMENT
valor I-TREATMENT
de I-TREATMENT
K+ I-TREATMENT
en I-TREATMENT
orina I-TREATMENT
de I-TREATMENT
5 I-TREATMENT
mEq/L. I-TREATMENT
La B-EVOLUTION
reposición I-EVOLUTION
hidroelectrolítica I-EVOLUTION
revirtió I-EVOLUTION
el I-EVOLUTION
cuadro I-EVOLUTION
en I-EVOLUTION
las I-EVOLUTION
primeras I-EVOLUTION
48 I-EVOLUTION
h I-EVOLUTION
de I-EVOLUTION
tratamiento. I-EVOLUTION
<EOS> I-EVOLUTION

Paciente B-PRESENT_ILLNESS
78 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino. I-PRESENT_ILLNESS
Hipertensión I-PRESENT_ILLNESS
arterial I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
tratamiento, I-PRESENT_ILLNESS
enfermedad I-PRESENT_ILLNESS
arterial I-PRESENT_ILLNESS
oclusiva I-PRESENT_ILLNESS
carotídea I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
estudio. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
Se I-PRESENT_ILLNESS
presenta I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
clínico I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
baja I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
peso I-PRESENT_ILLNESS
9 I-PRESENT_ILLNESS
kg, I-PRESENT_ILLNESS
disfagia I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
saciedad I-PRESENT_ILLNESS
precoz. I-PRESENT_ILLNESS
Endoscopia B-EXPLORATION
digestiva I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
lesión I-EXPLORATION
pediculada I-EXPLORATION
subcardial I-EXPLORATION
en I-EXPLORATION
cara I-EXPLORATION
posterior. I-EXPLORATION
Biopsia I-EXPLORATION
endoscópica: I-EXPLORATION
"tumor I-EXPLORATION
estromal I-EXPLORATION
fusocelular I-EXPLORATION
con I-EXPLORATION
> I-EXPLORATION
10 I-EXPLORATION
mitosis I-EXPLORATION
atípicas I-EXPLORATION
por I-EXPLORATION
50 I-EXPLORATION
campos", I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
GIST. I-EXPLORATION
<EOS> I-EXPLORATION
Tomografía I-EXPLORATION
axial I-EXPLORATION
computada I-EXPLORATION
de I-EXPLORATION
abdomen: I-EXPLORATION
lesión I-EXPLORATION
subcardial I-EXPLORATION
de I-EXPLORATION
6 I-EXPLORATION
cm I-EXPLORATION
diámetro I-EXPLORATION
mayor, I-EXPLORATION
sin I-EXPLORATION
adenopatías I-EXPLORATION
ni I-EXPLORATION
signos I-EXPLORATION
de I-EXPLORATION
diseminación I-EXPLORATION
sistémica, I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
confirma I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
tránsito I-EXPLORATION
esófago I-EXPLORATION
estómago I-EXPLORATION
y I-EXPLORATION
duodeno I-EXPLORATION
con I-EXPLORATION
sulfato I-EXPLORATION
de I-EXPLORATION
bario: I-EXPLORATION
lesión I-EXPLORATION
pediculada I-EXPLORATION
subcardial. I-EXPLORATION
Se B-TREATMENT
programa I-TREATMENT
resección I-TREATMENT
tumoral I-TREATMENT
laparoscópica: I-TREATMENT
Gastrotomía I-TREATMENT
anterior, I-TREATMENT
resección I-TREATMENT
de I-TREATMENT
tumor I-TREATMENT
con I-TREATMENT
sutura I-TREATMENT
mecánica I-TREATMENT
a I-TREATMENT
pedículo, I-TREATMENT
gastrorrafia, I-TREATMENT
biopsia I-TREATMENT
de I-TREATMENT
serosa I-TREATMENT
gástrica I-TREATMENT
y I-TREATMENT
peritoneo. I-TREATMENT
Postoperatorio B-EXPLORATION
sin I-EXPLORATION
complicaciones. I-EXPLORATION
<EOS> I-EXPLORATION
Biopsia: I-EXPLORATION
Carcinoma I-EXPLORATION
escamoso I-EXPLORATION
fusocelular I-EXPLORATION
sarcomatoide, I-EXPLORATION
polipoide I-EXPLORATION
y I-EXPLORATION
ulcerado I-EXPLORATION
6, I-EXPLORATION
5 I-EXPLORATION
x I-EXPLORATION
5 I-EXPLORATION
x I-EXPLORATION
4 I-EXPLORATION
cm. I-EXPLORATION
Margen I-EXPLORATION
positivo I-EXPLORATION
de I-EXPLORATION
pedículo. I-EXPLORATION
Sin I-EXPLORATION
permeaciones I-EXPLORATION
vasculares, I-EXPLORATION
linfáticas I-EXPLORATION
ni I-EXPLORATION
perineurales. I-EXPLORATION
Peritoneo I-EXPLORATION
y I-EXPLORATION
serosa I-EXPLORATION
gástrica: I-EXPLORATION
sin I-EXPLORATION
neoplasia. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
programa I-TREATMENT
para I-TREATMENT
gastrectomía I-TREATMENT
total I-TREATMENT
más I-TREATMENT
esofagectomía I-TREATMENT
distal I-TREATMENT
con I-TREATMENT
diagnóstico I-TREATMENT
de I-TREATMENT
carcinoma I-TREATMENT
escamoso I-TREATMENT
de I-TREATMENT
la I-TREATMENT
unión I-TREATMENT
gastroesofágica: I-TREATMENT
en I-TREATMENT
el I-TREATMENT
intraoperatorio I-TREATMENT
se I-TREATMENT
recibió I-TREATMENT
biopsia I-TREATMENT
rápida I-TREATMENT
de I-TREATMENT
límite I-TREATMENT
oral I-TREATMENT
infiltrado I-TREATMENT
por I-TREATMENT
carcinoma, I-TREATMENT
recorte I-TREATMENT
revela I-TREATMENT
compromiso I-TREATMENT
neoplásico I-TREATMENT
proximal I-TREATMENT
por I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
no I-TREATMENT
reconstituir I-TREATMENT
en I-TREATMENT
un I-TREATMENT
tiempo I-TREATMENT
por I-TREATMENT
las I-TREATMENT
condiciones I-TREATMENT
del I-TREATMENT
paciente I-TREATMENT
en I-TREATMENT
el I-TREATMENT
intraoperatorio, I-TREATMENT
efectuándose I-TREATMENT
esofagogastrectomía I-TREATMENT
total I-TREATMENT
transhiatal, I-TREATMENT
esofagostoma I-TREATMENT
cervical I-TREATMENT
terminal I-TREATMENT
transitorio I-TREATMENT
y I-TREATMENT
yeyunostomía I-TREATMENT
de I-TREATMENT
Wietzel, I-TREATMENT
dejando I-TREATMENT
para I-TREATMENT
un I-TREATMENT
segundo I-TREATMENT
tiempo I-TREATMENT
la I-TREATMENT
reconstitución I-TREATMENT
definitiva I-TREATMENT
del I-TREATMENT
tránsito I-TREATMENT
digestivo. I-TREATMENT
<EOS> I-TREATMENT
Biopsia B-EXPLORATION
definitiva: I-EXPLORATION
Carcinoma I-EXPLORATION
espinocelular I-EXPLORATION
fusocelular I-EXPLORATION
sarcomatoide I-EXPLORATION
esofágico I-EXPLORATION
con I-EXPLORATION
extensión I-EXPLORATION
hasta I-EXPLORATION
submucosa, I-EXPLORATION
compromiso I-EXPLORATION
de I-EXPLORATION
grupo I-EXPLORATION
1 I-EXPLORATION
y I-EXPLORATION
5 I-EXPLORATION
(4/37), I-EXPLORATION
sin I-EXPLORATION
adenopatías I-EXPLORATION
mediastínicas. I-EXPLORATION
Nódulo I-EXPLORATION
metastásico I-EXPLORATION
en I-EXPLORATION
epiplón I-EXPLORATION
menor I-EXPLORATION
correspondiente I-EXPLORATION
a I-EXPLORATION
ganglio I-EXPLORATION
N° I-EXPLORATION
5. I-EXPLORATION
Márgenes I-EXPLORATION
quirúrgicos I-EXPLORATION
sin I-EXPLORATION
neoplasia. I-EXPLORATION
<EOS> I-EXPLORATION
Al B-TREATMENT
mes I-TREATMENT
postoperatorio I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
reconstrucción I-TREATMENT
con I-TREATMENT
ascenso I-TREATMENT
de I-TREATMENT
colon I-TREATMENT
derecho I-TREATMENT
e I-TREATMENT
íleon I-TREATMENT
terminal I-TREATMENT
vía I-TREATMENT
retroesternal: I-TREATMENT
esófago-íleo I-TREATMENT
anastomosis I-TREATMENT
cervical I-TREATMENT
terminolateral, I-TREATMENT
transverso-duodeno I-TREATMENT
anastomosis I-TREATMENT
laterolateral, I-TREATMENT
íleo-transverso I-TREATMENT
anastomosis I-TREATMENT
latero-lateral I-TREATMENT
y I-TREATMENT
yeyunostomía I-TREATMENT
de I-TREATMENT
Wietzel. I-TREATMENT
<EOS> I-TREATMENT
Evolucionó B-EVOLUTION
con I-EVOLUTION
fístula I-EVOLUTION
cervical I-EVOLUTION
de I-EVOLUTION
bajo I-EVOLUTION
débito I-EVOLUTION
sin I-EVOLUTION
repercusión I-EVOLUTION
clínica, I-EVOLUTION
alta I-EVOLUTION
al I-EVOLUTION
día I-EVOLUTION
21 I-EVOLUTION
postoperatorio I-EVOLUTION
con I-EVOLUTION
régimen I-EVOLUTION
líquido I-EVOLUTION
y I-EVOLUTION
aporte I-EVOLUTION
por I-EVOLUTION
yeyunostomía. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente I-EVOLUTION
en I-EVOLUTION
excelentes I-EVOLUTION
condiciones I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
18 I-EVOLUTION
meses I-EVOLUTION
postoperatorios, I-EVOLUTION
autovalente, I-EVOLUTION
requirió I-EVOLUTION
dilatación I-EVOLUTION
endoscópica I-EVOLUTION
de I-EVOLUTION
anastomosis I-EVOLUTION
cervical, I-EVOLUTION
sin I-EVOLUTION
incidentes. I-EVOLUTION
<EOS> I-EVOLUTION

Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
41 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
fumador. B-PAST_MEDICAL_HISTORY
Historia B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
2 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
dorsal I-PRESENT_ILLNESS
irradiado I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
hombro I-PRESENT_ILLNESS
izquierdo, I-PRESENT_ILLNESS
intensidad I-PRESENT_ILLNESS
8/10 I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
respuesta I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
analgésicos, I-PRESENT_ILLNESS
tos I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
expectoración I-PRESENT_ILLNESS
mucosa, I-PRESENT_ILLNESS
baja I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
peso I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
sudoración I-PRESENT_ILLNESS
nocturna. I-PRESENT_ILLNESS
Examen B-EXPLORATION
físico I-EXPLORATION
inicial I-EXPLORATION
normal. I-EXPLORATION
Presentó I-EXPLORATION
anemia I-EXPLORATION
leve, I-EXPLORATION
VHS: I-EXPLORATION
96 I-EXPLORATION
mm/h, I-EXPLORATION
examen I-EXPLORATION
de I-EXPLORATION
orina, I-EXPLORATION
función I-EXPLORATION
renal, I-EXPLORATION
pruebas I-EXPLORATION
hepáticas I-EXPLORATION
y I-EXPLORATION
perfil I-EXPLORATION
lipídico I-EXPLORATION
normales. I-EXPLORATION
Tomografía I-EXPLORATION
computada I-EXPLORATION
de I-EXPLORATION
columna I-EXPLORATION
dorsal I-EXPLORATION
sin I-EXPLORATION
hallazgos I-EXPLORATION
significativos. I-EXPLORATION
Radiografía I-EXPLORATION
de I-EXPLORATION
tórax: I-EXPLORATION
nódulos I-EXPLORATION
subpleurales I-EXPLORATION
en I-EXPLORATION
vértices I-EXPLORATION
pulmonares I-EXPLORATION
y I-EXPLORATION
lóbulo I-EXPLORATION
superior I-EXPLORATION
izquierdo. I-EXPLORATION
Hemocultivos I-EXPLORATION
negativos. I-EXPLORATION
Ecotomografía I-EXPLORATION
abdominal I-EXPLORATION
normal, I-EXPLORATION
aTAC I-EXPLORATION
de I-EXPLORATION
tórax I-EXPLORATION
ateromatosis I-EXPLORATION
aórtica I-EXPLORATION
segmentaria I-EXPLORATION
en I-EXPLORATION
aorta I-EXPLORATION
descendente, I-EXPLORATION
con I-EXPLORATION
engrosamiento I-EXPLORATION
extraintimal, I-EXPLORATION
estenosis I-EXPLORATION
significativa I-EXPLORATION
de I-EXPLORATION
ostium I-EXPLORATION
en I-EXPLORATION
tronco I-EXPLORATION
celíaco. I-EXPLORATION
Nodulos I-EXPLORATION
pulmonares I-EXPLORATION
y I-EXPLORATION
condensaciones I-EXPLORATION
apicales I-EXPLORATION
bilaterales. I-EXPLORATION
VDRL: I-EXPLORATION
No I-EXPLORATION
reactivo, I-EXPLORATION
VIH I-EXPLORATION
negativo, I-EXPLORATION
PPD: I-EXPLORATION
10 I-EXPLORATION
mm. I-EXPLORATION
Quatiferon I-EXPLORATION
(-). I-EXPLORATION
El I-EXPLORATION
paciente I-EXPLORATION
evolucionó I-EXPLORATION
con I-EXPLORATION
escleritis I-EXPLORATION
bilateral I-EXPLORATION
y I-EXPLORATION
fiebre I-EXPLORATION
hasta I-EXPLORATION
37, I-EXPLORATION
8 I-EXPLORATION
°C. I-EXPLORATION
Se I-EXPLORATION
sospecha I-EXPLORATION
vasculitis I-EXPLORATION
de I-EXPLORATION
grandes I-EXPLORATION
vasos. I-EXPLORATION
Nuevos I-EXPLORATION
estudios I-EXPLORATION
demostraron I-EXPLORATION
ANCA I-EXPLORATION
citoplasmático I-EXPLORATION
(C): I-EXPLORATION
positivo, I-EXPLORATION
anti I-EXPLORATION
proteinasa I-EXPLORATION
3 I-EXPLORATION
(PR3) I-EXPLORATION
+6, I-EXPLORATION
5 I-EXPLORATION
(VN I-EXPLORATION
< I-EXPLORATION
1, I-EXPLORATION
2), I-EXPLORATION
C3 I-EXPLORATION
y I-EXPLORATION
C4 I-EXPLORATION
normales, I-EXPLORATION
ANA, I-EXPLORATION
anticuerpos I-EXPLORATION
anti-ADN I-EXPLORATION
y I-EXPLORATION
ENA I-EXPLORATION
negativos. I-EXPLORATION
Biopsia I-EXPLORATION
pulmonar: I-EXPLORATION
Nodulo I-EXPLORATION
con I-EXPLORATION
centro I-EXPLORATION
fibroso, I-EXPLORATION
necrosis I-EXPLORATION
y I-EXPLORATION
reacción I-EXPLORATION
histiocitaria, I-EXPLORATION
con I-EXPLORATION
células I-EXPLORATION
gigantes. I-EXPLORATION
Se I-EXPLORATION
reconoce I-EXPLORATION
neumonía I-EXPLORATION
organizativa I-EXPLORATION
periférica, I-EXPLORATION
signos I-EXPLORATION
de I-EXPLORATION
hemorragia I-EXPLORATION
antigua, I-EXPLORATION
concordante I-EXPLORATION
con I-EXPLORATION
PG. I-EXPLORATION
Recibió B-TREATMENT
corticoterapia I-TREATMENT
y I-TREATMENT
ciclofosfamida I-TREATMENT
oral I-TREATMENT
por I-TREATMENT
un I-TREATMENT
año I-TREATMENT
y I-TREATMENT
posteriormente I-TREATMENT
mantención I-TREATMENT
con I-TREATMENT
azatioprina. I-TREATMENT
Presentó B-EVOLUTION
buena I-EVOLUTION
respuesta I-EVOLUTION
clínica, I-EVOLUTION
normalización I-EVOLUTION
de I-EVOLUTION
los I-EVOLUTION
parámetros I-EVOLUTION
inflamatorios, I-EVOLUTION
radiografía I-EVOLUTION
y I-EVOLUTION
aTAC I-EVOLUTION
de I-EVOLUTION
tórax. I-EVOLUTION
Anti I-EVOLUTION
PR3 I-EVOLUTION
(-) I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
6 I-EVOLUTION
meses. I-EVOLUTION
<EOS> I-EVOLUTION

Presentamos B-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
caso I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
paciente I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
femenino, I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
75 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
e I-PAST_MEDICAL_HISTORY
hipotiroidismo I-PAST_MEDICAL_HISTORY
postquirúrgico I-PAST_MEDICAL_HISTORY
(por I-PAST_MEDICAL_HISTORY
bocio I-PAST_MEDICAL_HISTORY
nodular). I-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
agosto I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
2008 I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
9 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
caracterizado I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
fatigabilidad, I-PRESENT_ILLNESS
síncopes I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
repetición I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
disnea I-PRESENT_ILLNESS
progresiva. I-PRESENT_ILLNESS
Dentro B-EXPLORATION
del I-EXPLORATION
estudio I-EXPLORATION
se I-EXPLORATION
pesquisó I-EXPLORATION
anemia I-EXPLORATION
severa I-EXPLORATION
normocítica I-EXPLORATION
normocrómica, I-EXPLORATION
con I-EXPLORATION
hemoglobina I-EXPLORATION
de I-EXPLORATION
6, I-EXPLORATION
8 I-EXPLORATION
g/dL, I-EXPLORATION
leucocitos I-EXPLORATION
y I-EXPLORATION
plaquetas I-EXPLORATION
normales. I-EXPLORATION
Además I-EXPLORATION
destacó I-EXPLORATION
una I-EXPLORATION
VHS I-EXPLORATION
de I-EXPLORATION
140 I-EXPLORATION
mm/h. I-EXPLORATION
Por I-EXPLORATION
sospecha I-EXPLORATION
de I-EXPLORATION
MM I-EXPLORATION
se I-EXPLORATION
continuó I-EXPLORATION
estudio I-EXPLORATION
destacando I-EXPLORATION
proteínas I-EXPLORATION
totales I-EXPLORATION
14, I-EXPLORATION
6 I-EXPLORATION
g/dL, I-EXPLORATION
albúmina I-EXPLORATION
2 I-EXPLORATION
g/dL, I-EXPLORATION
calcio I-EXPLORATION
corregido I-EXPLORATION
10, I-EXPLORATION
8 I-EXPLORATION
mg/dL, I-EXPLORATION
creatinina: I-EXPLORATION
0, I-EXPLORATION
8 I-EXPLORATION
mg/dL, I-EXPLORATION
B2 I-EXPLORATION
microglobulina I-EXPLORATION
10, I-EXPLORATION
2 I-EXPLORATION
mg/L. I-EXPLORATION
La I-EXPLORATION
electroforesis I-EXPLORATION
de I-EXPLORATION
proteínas I-EXPLORATION
reveló I-EXPLORATION
un I-EXPLORATION
peak I-EXPLORATION
monoclonal I-EXPLORATION
en I-EXPLORATION
gamma I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
vio I-EXPLORATION
un I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
inmunoglobulina I-EXPLORATION
IgG I-EXPLORATION
de I-EXPLORATION
3.450 I-EXPLORATION
mg/dl, I-EXPLORATION
siendo I-EXPLORATION
el I-EXPLORATION
resto I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
Ig I-EXPLORATION
menores I-EXPLORATION
al I-EXPLORATION
rango I-EXPLORATION
normal. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
un I-EXPLORATION
mielograma I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
25% I-EXPLORATION
de I-EXPLORATION
plasmoblastos I-EXPLORATION
y I-EXPLORATION
plasmocitos, I-EXPLORATION
algunos I-EXPLORATION
binucleados. I-EXPLORATION
La I-EXPLORATION
serie I-EXPLORATION
radiológica I-EXPLORATION
reveló I-EXPLORATION
imágenes I-EXPLORATION
líticas I-EXPLORATION
en I-EXPLORATION
calota I-EXPLORATION
y I-EXPLORATION
en I-EXPLORATION
columna I-EXPLORATION
lumbar. I-EXPLORATION
Por I-EXPLORATION
lo I-EXPLORATION
tanto, I-EXPLORATION
se I-EXPLORATION
hizo I-EXPLORATION
el I-EXPLORATION
diagnóstico I-EXPLORATION
de I-EXPLORATION
MM I-EXPLORATION
IgG, I-EXPLORATION
con I-EXPLORATION
índices I-EXPLORATION
pronósticos I-EXPLORATION
de I-EXPLORATION
Durie I-EXPLORATION
Salmon I-EXPLORATION
IIIA I-EXPLORATION
e I-EXPLORATION
ISS I-EXPLORATION
de I-EXPLORATION
3 I-EXPLORATION
puntos. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
inició I-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
hidratación, I-TREATMENT
pamidronato I-TREATMENT
y I-TREATMENT
melfalán/prednisona, I-TREATMENT
recuperándose I-TREATMENT
la I-TREATMENT
hipercalcemia. I-TREATMENT
Recibió I-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
melfalán/prednisona I-TREATMENT
por I-TREATMENT
6 I-TREATMENT
ciclos I-TREATMENT
y I-TREATMENT
radioterapia I-TREATMENT
de I-TREATMENT
columna I-TREATMENT
lumbar, I-TREATMENT
destacando I-TREATMENT
en I-TREATMENT
los I-TREATMENT
controles I-TREATMENT
ambulatorios I-TREATMENT
mejoría I-TREATMENT
en I-TREATMENT
albúmina I-TREATMENT
y I-TREATMENT
calcemia, I-TREATMENT
pero I-TREATMENT
pancitopenia I-TREATMENT
progresiva I-TREATMENT
e I-TREATMENT
infecciones I-TREATMENT
urinarias I-TREATMENT
a I-TREATMENT
repetición. I-TREATMENT
En B-EVOLUTION
marzo I-EVOLUTION
de I-EVOLUTION
2009 I-EVOLUTION
estuvo I-EVOLUTION
hospitalizada I-EVOLUTION
por I-EVOLUTION
neumonía. I-EVOLUTION
En I-EVOLUTION
noviembre I-EVOLUTION
de I-EVOLUTION
2009 I-EVOLUTION
evolucionó I-EVOLUTION
con I-EVOLUTION
mayor I-EVOLUTION
dolor I-EVOLUTION
óseo I-EVOLUTION
y I-EVOLUTION
postración. I-EVOLUTION
Además, I-EVOLUTION
llamó I-EVOLUTION
la I-EVOLUTION
atención I-EVOLUTION
la I-EVOLUTION
aparición I-EVOLUTION
de I-EVOLUTION
lesiones I-EVOLUTION
cutáneas I-EVOLUTION
nodulares, I-EVOLUTION
violáceas, I-EVOLUTION
dolorosas I-EVOLUTION
de I-EVOLUTION
1, I-EVOLUTION
5 I-EVOLUTION
a I-EVOLUTION
2 I-EVOLUTION
cm I-EVOLUTION
en I-EVOLUTION
cuero I-EVOLUTION
cabelludo, I-EVOLUTION
ángulo I-EVOLUTION
mandibular I-EVOLUTION
izquierdo, I-EVOLUTION
cuello I-EVOLUTION
y I-EVOLUTION
dorso. I-EVOLUTION
Se B-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
punción I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
lesiones I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
celularidad I-EXPLORATION
constituida I-EXPLORATION
exclusivamente I-EXPLORATION
por I-EXPLORATION
células I-EXPLORATION
plasmáticas I-EXPLORATION
predominando I-EXPLORATION
proplasmocitos. I-EXPLORATION
La I-EXPLORATION
biopsia I-EXPLORATION
mostró I-EXPLORATION
igualmente I-EXPLORATION
infiltración I-EXPLORATION
por I-EXPLORATION
células I-EXPLORATION
plasmáticas. I-EXPLORATION
Debido B-TREATMENT
a I-TREATMENT
progresión I-TREATMENT
de I-TREATMENT
la I-TREATMENT
enfermedad I-TREATMENT
se I-TREATMENT
cambió I-TREATMENT
el I-TREATMENT
tratamiento I-TREATMENT
a I-TREATMENT
talidomida/dexametasona, I-TREATMENT
sin I-TREATMENT
resultados. I-TREATMENT
Se B-EVOLUTION
derivó I-EVOLUTION
a I-EVOLUTION
cuidados I-EVOLUTION
paliativos I-EVOLUTION
y I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
falleció I-EVOLUTION
2 I-EVOLUTION
meses I-EVOLUTION
después, I-EVOLUTION
por I-EVOLUTION
infección I-EVOLUTION
en I-EVOLUTION
mieloma I-EVOLUTION
refractario. I-EVOLUTION
<EOS> I-EVOLUTION

Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
transfusión I-PAST_MEDICAL_HISTORY
sanguínea I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
1972, I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
contexto I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
sangrado I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
úlcera I-PAST_MEDICAL_HISTORY
duodenal. I-PAST_MEDICAL_HISTORY
Además, I-PAST_MEDICAL_HISTORY
cáncer I-PAST_MEDICAL_HISTORY
testicular I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
15 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
hemicolectomía I-PAST_MEDICAL_HISTORY
izquierda I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
cáncer I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
colon I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
46 I-PAST_MEDICAL_HISTORY
años. I-PAST_MEDICAL_HISTORY
El B-PRESENT_ILLNESS
año I-PRESENT_ILLNESS
1994, I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
51 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
diagnosticó I-PRESENT_ILLNESS
cirrosis, I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
estudio I-PRESENT_ILLNESS
que B-EXPLORATION
mostró I-EXPLORATION
PCR I-EXPLORATION
positiva I-EXPLORATION
para I-EXPLORATION
VHC. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
biopsia I-EXPLORATION
hepática I-EXPLORATION
que I-EXPLORATION
mostraba I-EXPLORATION
hepatitis I-EXPLORATION
crónica I-EXPLORATION
con I-EXPLORATION
fibrosis I-EXPLORATION
grado I-EXPLORATION
III, I-EXPLORATION
sin I-EXPLORATION
cirrosis. I-EXPLORATION
Recibió B-TREATMENT
interferon I-TREATMENT
con I-TREATMENT
persistencia I-TREATMENT
de I-TREATMENT
PCR I-TREATMENT
+ I-TREATMENT
de I-TREATMENT
VHC. I-TREATMENT
Evolucionó B-EVOLUTION
con I-EVOLUTION
complicaciones I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
hipertensión I-EVOLUTION
portal, I-EVOLUTION
iniciando I-EVOLUTION
controles I-EVOLUTION
en I-EVOLUTION
nuestro I-EVOLUTION
centro I-EVOLUTION
en I-EVOLUTION
el I-EVOLUTION
2007. I-EVOLUTION
Ese I-EVOLUTION
año I-EVOLUTION
se I-EVOLUTION
diagnosticó I-EVOLUTION
hepatocarcinoma I-EVOLUTION
que B-TREATMENT
fue I-TREATMENT
quimioembolizado. I-TREATMENT
Se I-TREATMENT
trasplantó I-TREATMENT
en I-TREATMENT
mayo I-TREATMENT
de I-TREATMENT
2008. I-TREATMENT
Post I-TREATMENT
trasplante I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
inmunosupresión I-TREATMENT
con I-TREATMENT
prednisona I-TREATMENT
y I-TREATMENT
ciclosporina, I-TREATMENT
adicionando I-TREATMENT
micofenolato I-TREATMENT
por I-TREATMENT
falla I-TREATMENT
renal. I-TREATMENT
Se B-EVOLUTION
mantuvo I-EVOLUTION
con I-EVOLUTION
creatinina I-EVOLUTION
1, I-EVOLUTION
4-1, I-EVOLUTION
5 I-EVOLUTION
mg/dl, I-EVOLUTION
pero I-EVOLUTION
1 I-EVOLUTION
año I-EVOLUTION
y I-EVOLUTION
medio I-EVOLUTION
post I-EVOLUTION
trasplante I-EVOLUTION
tuvo I-EVOLUTION
alza I-EVOLUTION
hasta I-EVOLUTION
1, I-EVOLUTION
9-2, I-EVOLUTION
0 I-EVOLUTION
mg/dl. I-EVOLUTION
En B-TREATMENT
ese I-TREATMENT
momento I-TREATMENT
se I-TREATMENT
suspendió I-TREATMENT
ciclosporina I-TREATMENT
y I-TREATMENT
se I-TREATMENT
agregó I-TREATMENT
sirolimus. I-TREATMENT
Presentó B-EVOLUTION
úlceras I-EVOLUTION
orales, I-EVOLUTION
suspendiéndose B-TREATMENT
micofenolato. I-TREATMENT
Por B-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
falla I-EXPLORATION
renal I-EXPLORATION
se I-EXPLORATION
solicitó I-EXPLORATION
PCR I-EXPLORATION
para I-EXPLORATION
VHC, I-EXPLORATION
la I-EXPLORATION
que I-EXPLORATION
resultó I-EXPLORATION
negativa. I-EXPLORATION
Se I-EXPLORATION
solicitó I-EXPLORATION
carga I-EXPLORATION
viral I-EXPLORATION
en I-EXPLORATION
2 I-EXPLORATION
oportunidades, I-EXPLORATION
ambas I-EXPLORATION
negativas. I-EXPLORATION
Se I-EXPLORATION
interpretó I-EXPLORATION
como I-EXPLORATION
eliminación I-EXPLORATION
espontánea I-EXPLORATION
de I-EXPLORATION
VHC. I-EXPLORATION
<EOS> I-EXPLORATION

Paciente B-PRESENT_ILLNESS
femenino I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
41 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
Diabetes I-PAST_MEDICAL_HISTORY
Mellitus I-PAST_MEDICAL_HISTORY
tipo I-PAST_MEDICAL_HISTORY
2 I-PAST_MEDICAL_HISTORY
tratada I-PAST_MEDICAL_HISTORY
farmacológicamente. I-PAST_MEDICAL_HISTORY
Ingresa B-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
otorrinolaringología I-PRESENT_ILLNESS
(ORL) I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
Hospital I-PRESENT_ILLNESS
San I-PRESENT_ILLNESS
Juan I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
Dios I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
otalgia I-PRESENT_ILLNESS
derecha I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución, I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
inicio I-PRESENT_ILLNESS
insidioso, I-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
cual I-PRESENT_ILLNESS
aumenta I-PRESENT_ILLNESS
progresivamente I-PRESENT_ILLNESS
llegando I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
intensidad I-PRESENT_ILLNESS
10/10 I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
momento I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
consulta, I-PRESENT_ILLNESS
según I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
Escala I-PRESENT_ILLNESS
Visual I-PRESENT_ILLNESS
Análoga I-PRESENT_ILLNESS
(EVA). I-PRESENT_ILLNESS
Al B-EXPLORATION
examen I-EXPLORATION
la I-EXPLORATION
paciente I-EXPLORATION
se I-EXPLORATION
encontraba I-EXPLORATION
afebril, I-EXPLORATION
sin I-EXPLORATION
embargo I-EXPLORATION
se I-EXPLORATION
evidencia I-EXPLORATION
otorrea I-EXPLORATION
purulenta, I-EXPLORATION
hipoacusia I-EXPLORATION
y I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
volumen I-EXPLORATION
preauricular I-EXPLORATION
ipsilateral. I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
del I-EXPLORATION
cuadro I-EXPLORATION
arroja I-EXPLORATION
como I-EXPLORATION
diagnóstico I-EXPLORATION
una I-EXPLORATION
otitis I-EXPLORATION
externa I-EXPLORATION
necrotizante, I-EXPLORATION
además I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
mastoiditis I-EXPLORATION
ebúrnea. I-EXPLORATION
El B-TREATMENT
manejo I-TREATMENT
inicial I-TREATMENT
del I-TREATMENT
cuadro I-TREATMENT
consistió I-TREATMENT
en I-TREATMENT
la I-TREATMENT
hospitalización I-TREATMENT
y I-TREATMENT
el I-TREATMENT
tratamiento I-TREATMENT
antibiótico I-TREATMENT
con I-TREATMENT
un I-TREATMENT
esquema I-TREATMENT
empírico I-TREATMENT
enfocado I-TREATMENT
en I-TREATMENT
el I-TREATMENT
proceso I-TREATMENT
ótico I-TREATMENT
con I-TREATMENT
ceftazidima I-TREATMENT
más I-TREATMENT
clindamicina I-TREATMENT
endovenosa I-TREATMENT
y I-TREATMENT
ciprofloxacino I-TREATMENT
tópico. I-TREATMENT
<EOS> I-TREATMENT
El B-EXPLORATION
grado I-EXPLORATION
de I-EXPLORATION
compromiso I-EXPLORATION
es I-EXPLORATION
objetivado I-EXPLORATION
en I-EXPLORATION
las I-EXPLORATION
imágenes I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
tomografía I-EXPLORATION
axial I-EXPLORATION
computarizada I-EXPLORATION
(TAC) I-EXPLORATION
que I-EXPLORATION
muestra I-EXPLORATION
una I-EXPLORATION
franca I-EXPLORATION
zona I-EXPLORATION
de I-EXPLORATION
erosión I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
superficie I-EXPLORATION
ósea I-EXPLORATION
condilar I-EXPLORATION
mandibular I-EXPLORATION
derecha, I-EXPLORATION
con I-EXPLORATION
pérdida I-EXPLORATION
de I-EXPLORATION
capa I-EXPLORATION
cortical I-EXPLORATION
y I-EXPLORATION
destrucción I-EXPLORATION
hasta I-EXPLORATION
la I-EXPLORATION
medular I-EXPLORATION
ósea. I-EXPLORATION
Por I-EXPLORATION
lo I-EXPLORATION
anterior I-EXPLORATION
se I-EXPLORATION
interconsulta I-EXPLORATION
a I-EXPLORATION
cirugía I-EXPLORATION
maxilofacial. I-EXPLORATION
Al I-EXPLORATION
examen I-EXPLORATION
se I-EXPLORATION
aprecia I-EXPLORATION
el I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
volumen I-EXPLORATION
preauricular I-EXPLORATION
derecho I-EXPLORATION
de I-EXPLORATION
límites I-EXPLORATION
difusos, I-EXPLORATION
consistencia I-EXPLORATION
firme, I-EXPLORATION
con I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
temperatura I-EXPLORATION
local I-EXPLORATION
y I-EXPLORATION
eritema I-EXPLORATION
asociados. I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
funcional I-EXPLORATION
revela I-EXPLORATION
disminución I-EXPLORATION
considerable I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
apertura I-EXPLORATION
bucal I-EXPLORATION
de I-EXPLORATION
20 I-EXPLORATION
mm I-EXPLORATION
aproximadamente I-EXPLORATION
con I-EXPLORATION
movimientos I-EXPLORATION
de I-EXPLORATION
lateralidad I-EXPLORATION
conservados, I-EXPLORATION
asociándose I-EXPLORATION
a I-EXPLORATION
artralgia I-EXPLORATION
exacerbada I-EXPLORATION
por I-EXPLORATION
la I-EXPLORATION
función. I-EXPLORATION
Al I-EXPLORATION
examen I-EXPLORATION
hay I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
múltiples I-EXPLORATION
piezas I-EXPLORATION
dentarias I-EXPLORATION
posteriores I-EXPLORATION
tanto I-EXPLORATION
superiores I-EXPLORATION
como I-EXPLORATION
inferiores. I-EXPLORATION
La I-EXPLORATION
resonancia I-EXPLORATION
nuclear I-EXPLORATION
magnética I-EXPLORATION
(RNM) I-EXPLORATION
muestra I-EXPLORATION
cambios I-EXPLORATION
degenerativos I-EXPLORATION
y I-EXPLORATION
erosión I-EXPLORATION
a I-EXPLORATION
nivel I-EXPLORATION
cortical I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
vertiente I-EXPLORATION
anterior I-EXPLORATION
del I-EXPLORATION
cóndilo I-EXPLORATION
mandibular I-EXPLORATION
además I-EXPLORATION
de I-EXPLORATION
un I-EXPLORATION
proceso I-EXPLORATION
inflamatorio I-EXPLORATION
intracapsular I-EXPLORATION
diseminado I-EXPLORATION
a I-EXPLORATION
los I-EXPLORATION
músculos I-EXPLORATION
masticadores I-EXPLORATION
y I-EXPLORATION
al I-EXPLORATION
espacio I-EXPLORATION
temporal I-EXPLORATION
del I-EXPLORATION
mismo I-EXPLORATION
lado. I-EXPLORATION
Con I-EXPLORATION
los I-EXPLORATION
hallazgos I-EXPLORATION
clínicos I-EXPLORATION
e I-EXPLORATION
imagenológicos I-EXPLORATION
se I-EXPLORATION
plantea I-EXPLORATION
la I-EXPLORATION
hipótesis I-EXPLORATION
diagnóstica I-EXPLORATION
de I-EXPLORATION
artritis I-EXPLORATION
infecciosa I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
ATM I-EXPLORATION
por I-EXPLORATION
continuidad. I-EXPLORATION
<EOS> I-EXPLORATION
Luego B-TREATMENT
de I-TREATMENT
establecido I-TREATMENT
el I-TREATMENT
diagnóstico I-TREATMENT
de I-TREATMENT
otitis I-TREATMENT
necrotizante I-TREATMENT
y I-TREATMENT
mastoiditis, I-TREATMENT
es I-TREATMENT
ingresada I-TREATMENT
a I-TREATMENT
pabellón I-TREATMENT
por I-TREATMENT
parte I-TREATMENT
del I-TREATMENT
equipo I-TREATMENT
de I-TREATMENT
ORL I-TREATMENT
para I-TREATMENT
realizar I-TREATMENT
una I-TREATMENT
mastoidectomía I-TREATMENT
radical I-TREATMENT
modificada. I-TREATMENT
Posteriormente B-EXPLORATION
se I-EXPLORATION
realiza I-EXPLORATION
una I-EXPLORATION
punción I-EXPLORATION
intraarticular I-EXPLORATION
para I-EXPLORATION
estudio I-EXPLORATION
del I-EXPLORATION
contenido, I-EXPLORATION
donde I-EXPLORATION
se I-EXPLORATION
aprecia I-EXPLORATION
salida I-EXPLORATION
de I-EXPLORATION
contenido I-EXPLORATION
líquido I-EXPLORATION
turbio I-EXPLORATION
y I-EXPLORATION
seropurulento I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
envía I-EXPLORATION
a I-EXPLORATION
cultivo I-EXPLORATION
bacteriológico, I-EXPLORATION
el I-EXPLORATION
cual I-EXPLORATION
resulta I-EXPLORATION
negativo I-EXPLORATION
a I-EXPLORATION
las I-EXPLORATION
72 I-EXPLORATION
h I-EXPLORATION
de I-EXPLORATION
incubación. I-EXPLORATION
Se I-EXPLORATION
realiza I-EXPLORATION
además I-EXPLORATION
una I-EXPLORATION
artroscentesis I-EXPLORATION
con I-EXPLORATION
doble I-EXPLORATION
aguja I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
ATM I-EXPLORATION
según I-EXPLORATION
la I-EXPLORATION
técnica I-EXPLORATION
de I-EXPLORATION
Nitzan I-EXPLORATION
et I-EXPLORATION
al13, I-EXPLORATION
realizando I-EXPLORATION
un I-EXPLORATION
lavado I-EXPLORATION
profuso I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
articulación I-EXPLORATION
con I-EXPLORATION
solución I-EXPLORATION
salina. I-EXPLORATION
La B-EVOLUTION
paciente I-EVOLUTION
posterior I-EVOLUTION
a I-EVOLUTION
estas I-EVOLUTION
intervenciones I-EVOLUTION
mejora I-EVOLUTION
su I-EVOLUTION
condición I-EVOLUTION
general, I-EVOLUTION
siendo I-EVOLUTION
dada I-EVOLUTION
de I-EVOLUTION
alta I-EVOLUTION
con I-EVOLUTION
disminución I-EVOLUTION
franca I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
sintomatología, I-EVOLUTION
del I-EVOLUTION
aumento I-EVOLUTION
de I-EVOLUTION
volumen I-EVOLUTION
y I-EVOLUTION
una I-EVOLUTION
mejoría I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
apertura I-EVOLUTION
bucal I-EVOLUTION
llegando I-EVOLUTION
hasta I-EVOLUTION
los I-EVOLUTION
40 I-EVOLUTION
mm. I-EVOLUTION
<EOS> I-EVOLUTION
Al I-EVOLUTION
control I-EVOLUTION
al I-EVOLUTION
mes, I-EVOLUTION
se I-EVOLUTION
presenta I-EVOLUTION
asintomática. I-EVOLUTION
Sin I-EVOLUTION
embargo, I-EVOLUTION
se I-EVOLUTION
aprecia I-EVOLUTION
la I-EVOLUTION
presencia I-EVOLUTION
de I-EVOLUTION
un I-EVOLUTION
ruido I-EVOLUTION
articular I-EVOLUTION
en I-EVOLUTION
apertura I-EVOLUTION
y I-EVOLUTION
cierre I-EVOLUTION
el I-EVOLUTION
cual I-EVOLUTION
evoluciona I-EVOLUTION
a I-EVOLUTION
crépito I-EVOLUTION
en I-EVOLUTION
los I-EVOLUTION
siguientes I-EVOLUTION
controles. I-EVOLUTION
Es B-DERIVED_FROM/TO
derivada I-DERIVED_FROM/TO
a I-DERIVED_FROM/TO
tratamiento I-DERIVED_FROM/TO
protésico I-DERIVED_FROM/TO
para I-DERIVED_FROM/TO
mejorar I-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
estabilidad I-DERIVED_FROM/TO
oclusal I-DERIVED_FROM/TO
y I-DERIVED_FROM/TO
por I-DERIVED_FROM/TO
ende I-DERIVED_FROM/TO
disminuir I-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
sobrecarga I-DERIVED_FROM/TO
articular. I-DERIVED_FROM/TO
Se B-EXPLORATION
pide I-EXPLORATION
TAC I-EXPLORATION
de I-EXPLORATION
control I-EXPLORATION
a I-EXPLORATION
los I-EXPLORATION
2 I-EXPLORATION
meses I-EXPLORATION
el I-EXPLORATION
cual I-EXPLORATION
confirma I-EXPLORATION
una I-EXPLORATION
regeneración I-EXPLORATION
parcial I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
cortical I-EXPLORATION
ósea I-EXPLORATION
condilar. I-EXPLORATION
Actualmente, B-EVOLUTION
cuatro I-EVOLUTION
años I-EVOLUTION
después, I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
asintomática, I-EVOLUTION
con I-EVOLUTION
dinámica I-EVOLUTION
mandibular I-EVOLUTION
conservada. I-EVOLUTION
Sin I-EVOLUTION
embargo, I-EVOLUTION
como I-EVOLUTION
secuela I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
otitis I-EVOLUTION
media I-EVOLUTION
y I-EVOLUTION
posterior I-EVOLUTION
mastoiditis I-EVOLUTION
queda I-EVOLUTION
con I-EVOLUTION
alteraciones I-EVOLUTION
auditivas I-EVOLUTION
a I-EVOLUTION
la I-EVOLUTION
percepción I-EVOLUTION
de I-EVOLUTION
ruidos I-EVOLUTION
graves I-EVOLUTION
además I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
persistencia I-EVOLUTION
de I-EVOLUTION
crépito I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
ATM I-EVOLUTION
derecha I-EVOLUTION
debido I-EVOLUTION
al I-EVOLUTION
daño I-EVOLUTION
irreversible I-EVOLUTION
de I-EVOLUTION
los I-EVOLUTION
tejidos I-EVOLUTION
intraarticulares. I-EVOLUTION
<EOS> I-EVOLUTION

Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
45 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
80 I-PRESENT_ILLNESS
kg, I-PRESENT_ILLNESS
talla I-PRESENT_ILLNESS
1, I-PRESENT_ILLNESS
72 I-PRESENT_ILLNESS
m, I-PRESENT_ILLNESS
IMC I-PRESENT_ILLNESS
27, I-PRESENT_ILLNESS
11 I-PRESENT_ILLNESS
kg/m2, I-PRESENT_ILLNESS
portador B-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
dislipidemia, I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
familiares I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
DM. I-PAST_MEDICAL_HISTORY
Inicia B-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
caracterizado I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
polidipsia, I-PRESENT_ILLNESS
poliuria, I-PRESENT_ILLNESS
cansancio I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
calambres. I-PRESENT_ILLNESS
Al I-PRESENT_ILLNESS
mes I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
consulta I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
urgencia. I-PRESENT_ILLNESS
En B-EXPLORATION
el I-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
destacan I-EXPLORATION
piel I-EXPLORATION
y I-EXPLORATION
mucosas I-EXPLORATION
secas, I-EXPLORATION
acantosis I-EXPLORATION
nigricans I-EXPLORATION
en I-EXPLORATION
cuello, I-EXPLORATION
normotenso I-EXPLORATION
y I-EXPLORATION
pérdida I-EXPLORATION
de I-EXPLORATION
8 I-EXPLORATION
kilos I-EXPLORATION
de I-EXPLORATION
peso. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
realizan I-EXPLORATION
exámenes I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
hospitaliza I-EXPLORATION
con I-EXPLORATION
el I-EXPLORATION
diagnóstico I-EXPLORATION
de I-EXPLORATION
cetoacidosis I-EXPLORATION
diabética I-EXPLORATION
(CAD). I-EXPLORATION
Se B-TREATMENT
inicia I-TREATMENT
solución I-TREATMENT
solución I-TREATMENT
salina I-TREATMENT
0, I-TREATMENT
9% I-TREATMENT
1.000 I-TREATMENT
cc I-TREATMENT
con I-TREATMENT
cloruro I-TREATMENT
de I-TREATMENT
potasio I-TREATMENT
e I-TREATMENT
insulina I-TREATMENT
rápida I-TREATMENT
(IR) I-TREATMENT
8 I-TREATMENT
U I-TREATMENT
endovenosa. I-TREATMENT
A I-TREATMENT
la I-TREATMENT
hora, I-TREATMENT
se I-TREATMENT
continúa I-TREATMENT
con I-TREATMENT
el I-TREATMENT
aporte I-TREATMENT
de I-TREATMENT
volumen I-TREATMENT
(3.000 I-TREATMENT
cc) I-TREATMENT
e I-TREATMENT
IR I-TREATMENT
sc I-TREATMENT
(subcutánea) I-TREATMENT
cada I-TREATMENT
6 I-TREATMENT
h, I-TREATMENT
según I-TREATMENT
glicemias I-TREATMENT
capilares. I-TREATMENT
Se B-EXPLORATION
descarta I-EXPLORATION
foco I-EXPLORATION
infeccioso. I-EXPLORATION
A B-TREATMENT
las I-TREATMENT
8 I-TREATMENT
h I-TREATMENT
de I-TREATMENT
tratamiento, I-TREATMENT
al I-TREATMENT
revertir I-TREATMENT
la I-TREATMENT
acidosis I-TREATMENT
y I-TREATMENT
lograr I-TREATMENT
glicemias I-TREATMENT
< I-TREATMENT
250 I-TREATMENT
mg/dl, I-TREATMENT
se I-TREATMENT
inicia I-TREATMENT
terapia I-TREATMENT
basal I-TREATMENT
bolos I-TREATMENT
con I-TREATMENT
insulina I-TREATMENT
NPH I-TREATMENT
(Neutral I-TREATMENT
Protamine I-TREATMENT
Hagedorn) I-TREATMENT
e I-TREATMENT
IR I-TREATMENT
antes I-TREATMENT
del I-TREATMENT
desayuno I-TREATMENT
(AD) I-TREATMENT
y I-TREATMENT
cena, I-TREATMENT
más I-TREATMENT
refuerzos I-TREATMENT
de I-TREATMENT
IR I-TREATMENT
pre-prandiales, I-TREATMENT
lográndose B-EVOLUTION
una I-EVOLUTION
buena I-EVOLUTION
respuesta I-EVOLUTION
clínica. I-EVOLUTION
Al B-TREATMENT
alta I-TREATMENT
se I-TREATMENT
indica I-TREATMENT
régimen I-TREATMENT
con I-TREATMENT
180 I-TREATMENT
g I-TREATMENT
de I-TREATMENT
hidratos I-TREATMENT
de I-TREATMENT
carbono, I-TREATMENT
insulina I-TREATMENT
NPH I-TREATMENT
18 I-TREATMENT
U I-TREATMENT
AD I-TREATMENT
y I-TREATMENT
6 I-TREATMENT
U I-TREATMENT
a I-TREATMENT
las I-TREATMENT
22 I-TREATMENT
h, I-TREATMENT
con I-TREATMENT
automonitoreo I-TREATMENT
de I-TREATMENT
glicemias I-TREATMENT
capilares. I-TREATMENT
<EOS> I-TREATMENT
*HCO3 I-TREATMENT
Bicarbonato I-TREATMENT
de I-TREATMENT
sodio. I-TREATMENT
**HbA1c I-TREATMENT
Hemoglobina I-TREATMENT
glicosilada I-TREATMENT
A1c. I-TREATMENT
<EOS> I-TREATMENT
A B-EVOLUTION
las I-EVOLUTION
2 I-EVOLUTION
semanas I-EVOLUTION
el I-EVOLUTION
paciente I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
asintomático I-EVOLUTION
con I-EVOLUTION
glicemias I-EVOLUTION
capilares I-EVOLUTION
de I-EVOLUTION
ayunas I-EVOLUTION
70-110 I-EVOLUTION
mg/dl, I-EVOLUTION
pre-prandiales I-EVOLUTION
100-130 I-EVOLUTION
mg/dl I-EVOLUTION
y I-EVOLUTION
post-prandiales I-EVOLUTION
160-180 I-EVOLUTION
mg/dl. I-EVOLUTION
Dada B-TREATMENT
su I-TREATMENT
buena I-TREATMENT
evolución I-TREATMENT
se I-TREATMENT
disminuye I-TREATMENT
la I-TREATMENT
insulina I-TREATMENT
NPH I-TREATMENT
a I-TREATMENT
6 I-TREATMENT
U I-TREATMENT
a I-TREATMENT
las I-TREATMENT
22 I-TREATMENT
h I-TREATMENT
y I-TREATMENT
se I-TREATMENT
agrega I-TREATMENT
metformina I-TREATMENT
850 I-TREATMENT
mg I-TREATMENT
2 I-TREATMENT
veces I-TREATMENT
al I-TREATMENT
día. I-TREATMENT
Controlado B-EVOLUTION
al I-EVOLUTION
mes, I-EVOLUTION
relata I-EVOLUTION
episodios I-EVOLUTION
de I-EVOLUTION
hipoglicemias I-EVOLUTION
de I-EVOLUTION
60 I-EVOLUTION
mg/dl I-EVOLUTION
durante I-EVOLUTION
el I-EVOLUTION
día I-EVOLUTION
y I-EVOLUTION
los I-EVOLUTION
exámenes I-EVOLUTION
revelan I-EVOLUTION
buen I-EVOLUTION
control I-EVOLUTION
metabólico. I-EVOLUTION
<EOS> I-EVOLUTION
*HbA1c I-EVOLUTION
Hemoglobina I-EVOLUTION
glicosilada I-EVOLUTION
A1c. I-EVOLUTION
<EOS> I-EVOLUTION
Dado B-EXPLORATION
el I-EXPLORATION
inicio I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
DM I-EXPLORATION
en I-EXPLORATION
CAD I-EXPLORATION
(sospecha I-EXPLORATION
de I-EXPLORATION
DM1), I-EXPLORATION
en I-EXPLORATION
un I-EXPLORATION
paciente I-EXPLORATION
con I-EXPLORATION
características I-EXPLORATION
fenotípicas I-EXPLORATION
de I-EXPLORATION
DM2, I-EXPLORATION
se I-EXPLORATION
solicitaron I-EXPLORATION
marcadores I-EXPLORATION
inmunológicos I-EXPLORATION
para I-EXPLORATION
diabetes: I-EXPLORATION
anticuerpos I-EXPLORATION
anti I-EXPLORATION
células I-EXPLORATION
beta I-EXPLORATION
(ICA), I-EXPLORATION
anticuerpos I-EXPLORATION
anti I-EXPLORATION
insulina I-EXPLORATION
(IAA), I-EXPLORATION
anticuerpos I-EXPLORATION
anti I-EXPLORATION
ácido I-EXPLORATION
glutámico I-EXPLORATION
descarboxilasa I-EXPLORATION
(anti-GAD), I-EXPLORATION
anticuerpos I-EXPLORATION
anti I-EXPLORATION
tirosina I-EXPLORATION
fosfatasa I-EXPLORATION
(IA2), I-EXPLORATION
los I-EXPLORATION
que I-EXPLORATION
resultaron I-EXPLORATION
negativos. I-EXPLORATION
El I-EXPLORATION
péptido I-EXPLORATION
C I-EXPLORATION
en I-EXPLORATION
ayunas I-EXPLORATION
fue I-EXPLORATION
normal I-EXPLORATION
(3, I-EXPLORATION
2 I-EXPLORATION
ng/ml). I-EXPLORATION
En B-TREATMENT
estas I-TREATMENT
condiciones I-TREATMENT
se I-TREATMENT
suspendió I-TREATMENT
la I-TREATMENT
insulina, I-TREATMENT
manteniéndose I-TREATMENT
las I-TREATMENT
medidas I-TREATMENT
no I-TREATMENT
farmacológicas I-TREATMENT
y I-TREATMENT
la I-TREATMENT
metformina. I-TREATMENT
<EOS> I-TREATMENT
El B-EVOLUTION
paciente I-EVOLUTION
continúa I-EVOLUTION
en I-EVOLUTION
controles I-EVOLUTION
periódicos I-EVOLUTION
durante I-EVOLUTION
24 I-EVOLUTION
meses I-EVOLUTION
post I-EVOLUTION
alta, I-EVOLUTION
lográndose I-EVOLUTION
una I-EVOLUTION
reducción I-EVOLUTION
de I-EVOLUTION
10 I-EVOLUTION
kg I-EVOLUTION
de I-EVOLUTION
peso, I-EVOLUTION
glicemias I-EVOLUTION
de I-EVOLUTION
ayunas I-EVOLUTION
inferiores I-EVOLUTION
a100 I-EVOLUTION
mg/dl, I-EVOLUTION
HbA1c I-EVOLUTION
5, I-EVOLUTION
9%, I-EVOLUTION
y I-EVOLUTION
perfil I-EVOLUTION
lipídico I-EVOLUTION
y I-EVOLUTION
presión I-EVOLUTION
arterial I-EVOLUTION
normales. I-EVOLUTION
<EOS> I-EVOLUTION

Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
42 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
agricultor, B-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
importancia, I-PAST_MEDICAL_HISTORY
consulta B-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
múltiples I-PRESENT_ILLNESS
ocasiones I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
cefalea I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
sensación I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
pesadez I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
mareos I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
respuesta I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
analgésicos I-PRESENT_ILLNESS
comunes. I-PRESENT_ILLNESS
En B-EVOLUTION
su I-EVOLUTION
evolución I-EVOLUTION
presenta I-EVOLUTION
ataxia I-EVOLUTION
y I-EVOLUTION
lateropulsión I-EVOLUTION
derecha. I-EVOLUTION
Una I-EVOLUTION
semana I-EVOLUTION
previo I-EVOLUTION
a I-EVOLUTION
su I-EVOLUTION
ingreso I-EVOLUTION
presenta I-EVOLUTION
endoforia I-EVOLUTION
derecha, I-EVOLUTION
diplopia I-EVOLUTION
y I-EVOLUTION
postración I-EVOLUTION
en I-EVOLUTION
cama I-EVOLUTION
por I-EVOLUTION
vértigo I-EVOLUTION
intenso. I-EVOLUTION
Se B-EXPLORATION
realiza I-EXPLORATION
TC I-EXPLORATION
simple I-EXPLORATION
de I-EXPLORATION
cráneo I-EXPLORATION
que I-EXPLORATION
demostró I-EXPLORATION
masa I-EXPLORATION
en I-EXPLORATION
fosa I-EXPLORATION
posterior I-EXPLORATION
y I-EXPLORATION
hemorragia I-EXPLORATION
subaracnoidea I-EXPLORATION
por I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
traslada I-EXPLORATION
a I-EXPLORATION
hospital I-EXPLORATION
de I-EXPLORATION
nivel I-EXPLORATION
terciario. I-EXPLORATION
Ingresa B-EVOLUTION
al I-EVOLUTION
servicio I-EVOLUTION
de I-EVOLUTION
urgencias, I-EVOLUTION
consciente I-EVOLUTION
y I-EVOLUTION
orientado, I-EVOLUTION
con I-EVOLUTION
cefalea, I-EVOLUTION
diplopia I-EVOLUTION
e I-EVOLUTION
incapacidad I-EVOLUTION
para I-EVOLUTION
la I-EVOLUTION
marcha I-EVOLUTION
por I-EVOLUTION
vértigo. I-EVOLUTION
Su B-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
sólo I-EXPLORATION
demostró I-EXPLORATION
endoforia I-EXPLORATION
derecha, I-EXPLORATION
marcha I-EXPLORATION
inestable I-EXPLORATION
y I-EXPLORATION
lateropulsión I-EXPLORATION
derecha. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
RM I-EXPLORATION
simple I-EXPLORATION
y I-EXPLORATION
contrastada I-EXPLORATION
que I-EXPLORATION
reportó I-EXPLORATION
imagen I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
hemangioblastoma. I-EXPLORATION
En I-EXPLORATION
exámenes I-EXPLORATION
de I-EXPLORATION
ingreso I-EXPLORATION
se I-EXPLORATION
evidenció I-EXPLORATION
recuento I-EXPLORATION
plaquetario I-EXPLORATION
de I-EXPLORATION
10.000/mL, I-EXPLORATION
sin I-EXPLORATION
otras I-EXPLORATION
alteraciones I-EXPLORATION
en I-EXPLORATION
serie I-EXPLORATION
roja I-EXPLORATION
ni I-EXPLORATION
blanca I-EXPLORATION
por I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
difirió I-EXPLORATION
manejo I-EXPLORATION
quirúrgico I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
iniciaron I-EXPLORATION
estudios I-EXPLORATION
complementarios. I-EXPLORATION
El I-EXPLORATION
perfil I-EXPLORATION
de I-EXPLORATION
autoinmunidad I-EXPLORATION
(ANAS, I-EXPLORATION
ENAS, I-EXPLORATION
Coombs, I-EXPLORATION
inmunoglobulinas, I-EXPLORATION
anticoagulante I-EXPLORATION
lúpico I-EXPLORATION
y I-EXPLORATION
anticardiolipinas) I-EXPLORATION
infeccioso I-EXPLORATION
(VIH, I-EXPLORATION
Hepatitis I-EXPLORATION
B I-EXPLORATION
y I-EXPLORATION
C), I-EXPLORATION
pruebas I-EXPLORATION
de I-EXPLORATION
coagulación I-EXPLORATION
(PT, I-EXPLORATION
PTT) I-EXPLORATION
así I-EXPLORATION
como I-EXPLORATION
los I-EXPLORATION
niveles I-EXPLORATION
de I-EXPLORATION
micronutrientes I-EXPLORATION
fueron I-EXPLORATION
normales. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
consideró I-EXPLORATION
medición I-EXPLORATION
de I-EXPLORATION
dímero I-EXPLORATION
D I-EXPLORATION
y I-EXPLORATION
fibrinógeno I-EXPLORATION
ante I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
síntomas I-EXPLORATION
sugerentes I-EXPLORATION
de I-EXPLORATION
coagulopatía. I-EXPLORATION
<EOS> I-EXPLORATION
El B-EVOLUTION
paciente I-EVOLUTION
presentó I-EVOLUTION
deterioro I-EVOLUTION
neurológico I-EVOLUTION
por B-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
llevar I-TREATMENT
a I-TREATMENT
cirugía I-TREATMENT
urgente I-TREATMENT
previo I-TREATMENT
soporte I-TREATMENT
transfusional I-TREATMENT
de I-TREATMENT
plaquetas I-TREATMENT
para I-TREATMENT
resección I-TREATMENT
de I-TREATMENT
la I-TREATMENT
masa I-TREATMENT
en I-TREATMENT
SNC. I-TREATMENT
Por I-TREATMENT
trepanación I-TREATMENT
occipital I-TREATMENT
derecha I-TREATMENT
se I-TREATMENT
pasa I-TREATMENT
catéter I-TREATMENT
de I-TREATMENT
derivación I-TREATMENT
ventricular I-TREATMENT
externa I-TREATMENT
al I-TREATMENT
ventrículo I-TREATMENT
lateral I-TREATMENT
ipsilateral, I-TREATMENT
con I-TREATMENT
obtención I-TREATMENT
de I-TREATMENT
LCR I-TREATMENT
a I-TREATMENT
presión. I-TREATMENT
Se I-TREATMENT
identificó I-TREATMENT
tumor I-TREATMENT
en I-TREATMENT
fosa I-TREATMENT
posterior, I-TREATMENT
realizándose I-TREATMENT
drenaje I-TREATMENT
de I-TREATMENT
quiste I-TREATMENT
tumoral I-TREATMENT
aspecto I-TREATMENT
de I-TREATMENT
hemangioblastoma, I-TREATMENT
muy I-TREATMENT
vascularizado, I-TREATMENT
con I-TREATMENT
resección I-TREATMENT
macroscópica I-TREATMENT
total. I-TREATMENT
El B-EXPLORATION
informe I-EXPLORATION
de I-EXPLORATION
patología I-EXPLORATION
fue I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
hemangioblastoma. I-EXPLORATION
Dada I-EXPLORATION
la I-EXPLORATION
asociación I-EXPLORATION
con I-EXPLORATION
el I-EXPLORATION
síndrome I-EXPLORATION
de I-EXPLORATION
Von I-EXPLORATION
Hippel I-EXPLORATION
Lindau, I-EXPLORATION
se I-EXPLORATION
consideró I-EXPLORATION
adicionalmente I-EXPLORATION
búsqueda I-EXPLORATION
de I-EXPLORATION
otros I-EXPLORATION
tumores I-EXPLORATION
a I-EXPLORATION
nivel I-EXPLORATION
abdominal I-EXPLORATION
con I-EXPLORATION
ecografía I-EXPLORATION
la I-EXPLORATION
cual I-EXPLORATION
fue I-EXPLORATION
negativa. I-EXPLORATION
<EOS> I-EXPLORATION
Es B-EVOLUTION
trasladado I-EVOLUTION
a I-EVOLUTION
unidad I-EVOLUTION
de I-EVOLUTION
cuidado I-EVOLUTION
crítico I-EVOLUTION
con I-EVOLUTION
excelente I-EVOLUTION
respuesta I-EVOLUTION
neurológica I-EVOLUTION
sin I-EVOLUTION
resolución I-EVOLUTION
de I-EVOLUTION
trombocitopenia I-EVOLUTION
–entre I-EVOLUTION
5.000 I-EVOLUTION
y I-EVOLUTION
169.000/mL– I-EVOLUTION
requiriendo I-EVOLUTION
en I-EVOLUTION
varias I-EVOLUTION
ocasiones I-EVOLUTION
soporte I-EVOLUTION
transfusional I-EVOLUTION
buscando I-EVOLUTION
recuentos I-EVOLUTION
> I-EVOLUTION
100.000/mL. I-EVOLUTION
El B-EXPLORATION
seguimiento I-EXPLORATION
tomográfico I-EXPLORATION
(Día I-EXPLORATION
2 I-EXPLORATION
y I-EXPLORATION
7 I-EXPLORATION
postoperatorio) I-EXPLORATION
demostraban I-EXPLORATION
hematoma I-EXPLORATION
subdural I-EXPLORATION
con I-EXPLORATION
signos I-EXPLORATION
de I-EXPLORATION
herniación I-EXPLORATION
en I-EXPLORATION
resolución. I-EXPLORATION
Es I-EXPLORATION
llevado I-EXPLORATION
a I-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
médula I-EXPLORATION
ósea I-EXPLORATION
(mielograma, I-EXPLORATION
biopsia, I-EXPLORATION
cariotipo) I-EXPLORATION
todos I-EXPLORATION
normales I-EXPLORATION
y B-TREATMENT
con I-TREATMENT
sospecha I-TREATMENT
de I-TREATMENT
púrpura I-TREATMENT
trombócitopenica I-TREATMENT
inmune I-TREATMENT
(PTI) I-TREATMENT
se I-TREATMENT
indicó I-TREATMENT
glucocorticoides I-TREATMENT
(hidrocortisona I-TREATMENT
50 I-TREATMENT
mg I-TREATMENT
c/6 I-TREATMENT
h I-TREATMENT
por I-TREATMENT
2 I-TREATMENT
días, I-TREATMENT
dexametasona I-TREATMENT
4 I-TREATMENT
mg I-TREATMENT
c/6 I-TREATMENT
h I-TREATMENT
por I-TREATMENT
10 I-TREATMENT
días) I-TREATMENT
sin I-TREATMENT
respuesta. I-TREATMENT
En I-TREATMENT
vista I-TREATMENT
de I-TREATMENT
riesgo I-TREATMENT
de I-TREATMENT
sangrado I-TREATMENT
intracerebral I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
aplicar I-TREATMENT
inmunoglobulina I-TREATMENT
IV I-TREATMENT
1 I-TREATMENT
g/kg I-TREATMENT
por I-TREATMENT
dos I-TREATMENT
dosis I-TREATMENT
espaciadas I-TREATMENT
una I-TREATMENT
semana I-TREATMENT
más I-TREATMENT
prednisona I-TREATMENT
a I-TREATMENT
1 I-TREATMENT
mg/kg/día I-TREATMENT
sin I-TREATMENT
mejoría I-TREATMENT
clínica I-TREATMENT
por I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
programó I-TREATMENT
para I-TREATMENT
esplenectomía I-TREATMENT
laparoscópica I-TREATMENT
20 I-TREATMENT
días I-TREATMENT
después I-TREATMENT
del I-TREATMENT
procedimiento I-TREATMENT
neuroquirúrgico. I-TREATMENT
El I-TREATMENT
procedimiento I-TREATMENT
se I-TREATMENT
desarrolla I-TREATMENT
sin I-TREATMENT
complicaciones I-TREATMENT
y I-TREATMENT
presenta I-TREATMENT
recuento I-TREATMENT
plaquetario I-TREATMENT
de I-TREATMENT
165.000/mL I-TREATMENT
en I-TREATMENT
el I-TREATMENT
postoperatorio I-TREATMENT
inmediato, I-TREATMENT
con I-TREATMENT
bazo I-TREATMENT
histológicamente I-TREATMENT
normal. I-TREATMENT
Cuarenta B-EVOLUTION
y I-EVOLUTION
ocho I-EVOLUTION
horas I-EVOLUTION
después, I-EVOLUTION
el I-EVOLUTION
paciente I-EVOLUTION
presenta I-EVOLUTION
nuevo I-EVOLUTION
deterioro I-EVOLUTION
neurológico I-EVOLUTION
requiriendo I-EVOLUTION
reingreso I-EVOLUTION
a I-EVOLUTION
UCI. I-EVOLUTION
Recuento B-EXPLORATION
plaquetario I-EXPLORATION
126.000/mL, I-EXPLORATION
tromboelastografía I-EXPLORATION
con I-EXPLORATION
MA I-EXPLORATION
elevado I-EXPLORATION
sugerente I-EXPLORATION
de I-EXPLORATION
hiperagregabilidad I-EXPLORATION
plaquetaria I-EXPLORATION
y I-EXPLORATION
TC I-EXPLORATION
de I-EXPLORATION
cráneo I-EXPLORATION
con I-EXPLORATION
hematoma I-EXPLORATION
subdural I-EXPLORATION
derecho I-EXPLORATION
subagudo I-EXPLORATION
con I-EXPLORATION
efecto I-EXPLORATION
de I-EXPLORATION
masa I-EXPLORATION
y I-EXPLORATION
tendencia I-EXPLORATION
a I-EXPLORATION
herniación I-EXPLORATION
con I-EXPLORATION
hipodensidad I-EXPLORATION
de I-EXPLORATION
todo I-EXPLORATION
el I-EXPLORATION
hemisferio I-EXPLORATION
cerebral I-EXPLORATION
ipsilateral I-EXPLORATION
sugestivo I-EXPLORATION
de I-EXPLORATION
isquemia I-EXPLORATION
por B-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
lleva I-TREATMENT
nuevamente I-TREATMENT
a I-TREATMENT
cirugía I-TREATMENT
de I-TREATMENT
emergencia I-TREATMENT
–drepanotomía–. I-TREATMENT
El B-EXPLORATION
TC I-EXPLORATION
posterior I-EXPLORATION
no I-EXPLORATION
demostró I-EXPLORATION
cambios I-EXPLORATION
significativos. I-EXPLORATION
Con B-EVOLUTION
estos I-EVOLUTION
hallazgos I-EVOLUTION
se I-EVOLUTION
retira I-EVOLUTION
sedación I-EVOLUTION
del I-EVOLUTION
paciente, I-EVOLUTION
2 I-EVOLUTION
días I-EVOLUTION
después I-EVOLUTION
presenta I-EVOLUTION
hipernatremia I-EVOLUTION
y I-EVOLUTION
fiebre, I-EVOLUTION
luego I-EVOLUTION
de I-EVOLUTION
dos I-EVOLUTION
evaluaciones I-EVOLUTION
se I-EVOLUTION
declara I-EVOLUTION
muerte I-EVOLUTION
encefálica. I-EVOLUTION
<EOS> I-EVOLUTION

Paciente B-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino, I-PRESENT_ILLNESS
81 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
portador B-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
poliartritis I-PAST_MEDICAL_HISTORY
simétrica I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
manos, I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
un I-PAST_MEDICAL_HISTORY
inicio I-PAST_MEDICAL_HISTORY
fue I-PAST_MEDICAL_HISTORY
catalogado I-PAST_MEDICAL_HISTORY
como I-PAST_MEDICAL_HISTORY
artritis I-PAST_MEDICAL_HISTORY
seronegativa; I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
más I-PAST_MEDICAL_HISTORY
tarde I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
agregó I-PAST_MEDICAL_HISTORY
cuadro I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
dolor I-PAST_MEDICAL_HISTORY
urente I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
parestesias I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
extremidades I-PAST_MEDICAL_HISTORY
inferiores. I-PAST_MEDICAL_HISTORY
Se I-PAST_MEDICAL_HISTORY
repitió I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
estudio, I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
dado I-PAST_MEDICAL_HISTORY
MPO I-PAST_MEDICAL_HISTORY
(+) I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
biopsia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
nervio I-PAST_MEDICAL_HISTORY
sural I-PAST_MEDICAL_HISTORY
compatible I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
vasculitis I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
vaso I-PAST_MEDICAL_HISTORY
pequeño, I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
estableció I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
diagnóstico I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
vasculitis I-PAST_MEDICAL_HISTORY
asociada I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
ANCA I-PAST_MEDICAL_HISTORY
(MPO I-PAST_MEDICAL_HISTORY
(+)), I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
compromiso I-PAST_MEDICAL_HISTORY
pulmonar I-PAST_MEDICAL_HISTORY
(Usual I-PAST_MEDICAL_HISTORY
Interstitial I-PAST_MEDICAL_HISTORY
Pneumonia I-PAST_MEDICAL_HISTORY
[UIP], I-PAST_MEDICAL_HISTORY
demostrado I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
tomografía I-PAST_MEDICAL_HISTORY
axial I-PAST_MEDICAL_HISTORY
computada I-PAST_MEDICAL_HISTORY
[TAC]), I-PAST_MEDICAL_HISTORY
articular I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
neurológico. I-PAST_MEDICAL_HISTORY
Además, I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
cardiopatía I-PAST_MEDICAL_HISTORY
coronaria, I-PAST_MEDICAL_HISTORY
insuficiencia I-PAST_MEDICAL_HISTORY
cardíaca I-PAST_MEDICAL_HISTORY
CF I-PAST_MEDICAL_HISTORY
I-II I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
enfermedad I-PAST_MEDICAL_HISTORY
renal I-PAST_MEDICAL_HISTORY
crónica I-PAST_MEDICAL_HISTORY
(ERC) I-PAST_MEDICAL_HISTORY
etapa I-PAST_MEDICAL_HISTORY
3. I-PAST_MEDICAL_HISTORY
Desde I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
punto I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
vista I-PAST_MEDICAL_HISTORY
cardiológico, I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
paciente I-PAST_MEDICAL_HISTORY
había I-PAST_MEDICAL_HISTORY
presentado I-PAST_MEDICAL_HISTORY
un I-PAST_MEDICAL_HISTORY
síndrome I-PAST_MEDICAL_HISTORY
coronario I-PAST_MEDICAL_HISTORY
agudo I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
año I-PAST_MEDICAL_HISTORY
2012, I-PAST_MEDICAL_HISTORY
cuya I-PAST_MEDICAL_HISTORY
coronariografía I-PAST_MEDICAL_HISTORY
mostraba I-PAST_MEDICAL_HISTORY
oclusión I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
ramo I-PAST_MEDICAL_HISTORY
marginal I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
estenosis I-PAST_MEDICAL_HISTORY
no I-PAST_MEDICAL_HISTORY
significativa I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
vasos I-PAST_MEDICAL_HISTORY
principales. I-PAST_MEDICAL_HISTORY
Ecocardiograma I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
hipertrofia I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
ventrículo I-PAST_MEDICAL_HISTORY
izquierdo I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
leve I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
arteria I-PAST_MEDICAL_HISTORY
pulmonar. I-PAST_MEDICAL_HISTORY
Al I-PAST_MEDICAL_HISTORY
momento I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
diagnóstico I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
intentó I-PAST_MEDICAL_HISTORY
usar I-PAST_MEDICAL_HISTORY
ciclofosfamida I-PAST_MEDICAL_HISTORY
oral, I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
embargo, I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
paciente I-PAST_MEDICAL_HISTORY
presentó I-PAST_MEDICAL_HISTORY
pancitopenia I-PAST_MEDICAL_HISTORY
severa, I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
lo I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
suspendió. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
En I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
mantención I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
4 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
prednisona I-PAST_MEDICAL_HISTORY
5 I-PAST_MEDICAL_HISTORY
mg/día I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
azatioprina I-PAST_MEDICAL_HISTORY
50 I-PAST_MEDICAL_HISTORY
mg/día. I-PAST_MEDICAL_HISTORY
Estable I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
asintomático. I-PAST_MEDICAL_HISTORY
Las I-PAST_MEDICAL_HISTORY
semanas I-PAST_MEDICAL_HISTORY
previas I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
última I-PAST_MEDICAL_HISTORY
consulta I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
diagnosticó I-PAST_MEDICAL_HISTORY
reactivación I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
su I-PAST_MEDICAL_HISTORY
vasculitis, I-PAST_MEDICAL_HISTORY
caracterizada I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
reinicio I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
dolor I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
parestesias I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
extremidades I-PAST_MEDICAL_HISTORY
inferiores, I-PAST_MEDICAL_HISTORY
intenso I-PAST_MEDICAL_HISTORY
livedo I-PAST_MEDICAL_HISTORY
reticularis I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
aumento I-PAST_MEDICAL_HISTORY
progresivo I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
VHS I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
PCR, I-PAST_MEDICAL_HISTORY
decidiéndose I-PAST_MEDICAL_HISTORY
inducción I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
remisión I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
rituximab I-PAST_MEDICAL_HISTORY
(no I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
tomó I-PAST_MEDICAL_HISTORY
nueva I-PAST_MEDICAL_HISTORY
biopsia). I-PAST_MEDICAL_HISTORY
Exámenes I-PAST_MEDICAL_HISTORY
previos I-PAST_MEDICAL_HISTORY
al I-PAST_MEDICAL_HISTORY
procedimiento: I-PAST_MEDICAL_HISTORY
Hemoglobina I-PAST_MEDICAL_HISTORY
13, I-PAST_MEDICAL_HISTORY
9 I-PAST_MEDICAL_HISTORY
g/dL, I-PAST_MEDICAL_HISTORY
glóbulos I-PAST_MEDICAL_HISTORY
blancos I-PAST_MEDICAL_HISTORY
12.300/mm³, I-PAST_MEDICAL_HISTORY
VHS I-PAST_MEDICAL_HISTORY
64 I-PAST_MEDICAL_HISTORY
mm/h, I-PAST_MEDICAL_HISTORY
creatinina I-PAST_MEDICAL_HISTORY
1, I-PAST_MEDICAL_HISTORY
39 I-PAST_MEDICAL_HISTORY
mg/dL, I-PAST_MEDICAL_HISTORY
nitrógeno I-PAST_MEDICAL_HISTORY
ureico I-PAST_MEDICAL_HISTORY
23 I-PAST_MEDICAL_HISTORY
mg/dL, I-PAST_MEDICAL_HISTORY
glicemia I-PAST_MEDICAL_HISTORY
101 I-PAST_MEDICAL_HISTORY
mg/dL, I-PAST_MEDICAL_HISTORY
albúmina I-PAST_MEDICAL_HISTORY
4 I-PAST_MEDICAL_HISTORY
g/dL, I-PAST_MEDICAL_HISTORY
colesterol I-PAST_MEDICAL_HISTORY
total I-PAST_MEDICAL_HISTORY
145 I-PAST_MEDICAL_HISTORY
mg/dl, I-PAST_MEDICAL_HISTORY
bilirrubina I-PAST_MEDICAL_HISTORY
total I-PAST_MEDICAL_HISTORY
0, I-PAST_MEDICAL_HISTORY
5 I-PAST_MEDICAL_HISTORY
mg/dL. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Se I-PAST_MEDICAL_HISTORY
hospitalizó I-PAST_MEDICAL_HISTORY
para I-PAST_MEDICAL_HISTORY
su I-PAST_MEDICAL_HISTORY
administración, I-PAST_MEDICAL_HISTORY
premedicándose I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
metilprednisolona I-PAST_MEDICAL_HISTORY
(125 I-PAST_MEDICAL_HISTORY
mg), I-PAST_MEDICAL_HISTORY
transcurriendo I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
incidentes I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
enviado I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
su I-PAST_MEDICAL_HISTORY
domicilio. I-PAST_MEDICAL_HISTORY
Sin I-PAST_MEDICAL_HISTORY
embargo, I-PAST_MEDICAL_HISTORY
aproximadamente I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
las I-PAST_MEDICAL_HISTORY
24 I-PAST_MEDICAL_HISTORY
h I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
su I-PAST_MEDICAL_HISTORY
infusión I-PAST_MEDICAL_HISTORY
inició I-PAST_MEDICAL_HISTORY
fiebre I-PAST_MEDICAL_HISTORY
hasta I-PAST_MEDICAL_HISTORY
39, I-PAST_MEDICAL_HISTORY
8 I-PAST_MEDICAL_HISTORY
°C, I-PAST_MEDICAL_HISTORY
dificultad I-PAST_MEDICAL_HISTORY
respiratoria, I-PAST_MEDICAL_HISTORY
tos I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
expectoración I-PAST_MEDICAL_HISTORY
mucopurulenta I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
marcado I-PAST_MEDICAL_HISTORY
compromiso I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
estado I-PAST_MEDICAL_HISTORY
general. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
urgencias, I-PRESENT_ILLNESS
donde I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
evidenció I-PRESENT_ILLNESS
febril I-PRESENT_ILLNESS
(38, I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
°C), I-PRESENT_ILLNESS
hipotenso I-PRESENT_ILLNESS
(PAM I-PRESENT_ILLNESS
49 I-PRESENT_ILLNESS
mmHg), I-PRESENT_ILLNESS
desaturando I-PRESENT_ILLNESS
89% I-PRESENT_ILLNESS
ambiental I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
polipneico I-PRESENT_ILLNESS
(FR I-PRESENT_ILLNESS
29x’). I-PRESENT_ILLNESS
Al B-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
se I-EXPLORATION
constató I-EXPLORATION
mal I-EXPLORATION
perfundido I-EXPLORATION
y I-EXPLORATION
con I-EXPLORATION
uso I-EXPLORATION
de I-EXPLORATION
musculatura I-EXPLORATION
accesoria. I-EXPLORATION
Exámenes I-EXPLORATION
de I-EXPLORATION
laboratorio: I-EXPLORATION
Hemoglobina I-EXPLORATION
14, I-EXPLORATION
4 I-EXPLORATION
g/dL, I-EXPLORATION
leucocitos I-EXPLORATION
5.200/mm³, I-EXPLORATION
proteína I-EXPLORATION
C I-EXPLORATION
reactiva I-EXPLORATION
177 I-EXPLORATION
mg/L, I-EXPLORATION
gases I-EXPLORATION
arteriales: I-EXPLORATION
pH I-EXPLORATION
7, I-EXPLORATION
49; I-EXPLORATION
pO2 I-EXPLORATION
53 I-EXPLORATION
mmHg; I-EXPLORATION
HCO3 I-EXPLORATION
19 I-EXPLORATION
mEq/L; I-EXPLORATION
SatO2 I-EXPLORATION
91%; I-EXPLORATION
PaFi I-EXPLORATION
254, I-EXPLORATION
lactato I-EXPLORATION
arterial I-EXPLORATION
23 I-EXPLORATION
mmol, I-EXPLORATION
troponina I-EXPLORATION
0, I-EXPLORATION
07 I-EXPLORATION
ng/mL, I-EXPLORATION
BNP I-EXPLORATION
254 I-EXPLORATION
ug/l, I-EXPLORATION
creatinina I-EXPLORATION
1, I-EXPLORATION
87 I-EXPLORATION
mg/dL, I-EXPLORATION
nitrógeno I-EXPLORATION
ureico I-EXPLORATION
33 I-EXPLORATION
mg/dL. I-EXPLORATION
Radiografía I-EXPLORATION
de I-EXPLORATION
tórax: I-EXPLORATION
cardiomegalia, I-EXPLORATION
hallazgos I-EXPLORATION
secundarios I-EXPLORATION
a I-EXPLORATION
UIP, I-EXPLORATION
sin I-EXPLORATION
signos I-EXPLORATION
de I-EXPLORATION
condensación, I-EXPLORATION
congestión I-EXPLORATION
ni I-EXPLORATION
derrame I-EXPLORATION
pleural I-EXPLORATION
evidentes. I-EXPLORATION
Electrocardiograma: I-EXPLORATION
ritmo I-EXPLORATION
sinusal, I-EXPLORATION
sin I-EXPLORATION
alteraciones. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
volemizó I-EXPLORATION
vigorosamente, I-EXPLORATION
persistiendo I-EXPLORATION
hipotenso, I-EXPLORATION
por I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
ingresó I-EXPLORATION
a I-EXPLORATION
UTI I-EXPLORATION
para I-EXPLORATION
manejo. I-EXPLORATION
Se B-TREATMENT
tomaron I-TREATMENT
hemocultivos I-TREATMENT
y I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
empíricamente I-TREATMENT
tratamiento I-TREATMENT
antimicrobiano I-TREATMENT
con I-TREATMENT
moxifloxacino I-TREATMENT
(completa I-TREATMENT
10 I-TREATMENT
días) I-TREATMENT
y I-TREATMENT
oseltamivir I-TREATMENT
(completa I-TREATMENT
5 I-TREATMENT
días). I-TREATMENT
Además, I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
uso I-TREATMENT
de I-TREATMENT
vasoactivos I-TREATMENT
y I-TREATMENT
corticoides I-TREATMENT
en I-TREATMENT
dosis I-TREATMENT
de I-TREATMENT
estrés. I-TREATMENT
<EOS> I-TREATMENT
Evolucionó I-TREATMENT
con I-TREATMENT
requerimientos I-TREATMENT
de I-TREATMENT
noradrenalina I-TREATMENT
hasta I-TREATMENT
0, I-TREATMENT
1 I-TREATMENT
mcg/kg/min, I-TREATMENT
que I-TREATMENT
se I-TREATMENT
lograron I-TREATMENT
suspender I-TREATMENT
a I-TREATMENT
las I-TREATMENT
12 I-TREATMENT
h. I-TREATMENT
Se B-EXPLORATION
obtuvo I-EXPLORATION
muestra I-EXPLORATION
para I-EXPLORATION
panel I-EXPLORATION
viral I-EXPLORATION
y I-EXPLORATION
PCR I-EXPLORATION
viral I-EXPLORATION
(-), I-EXPLORATION
hemocultivos I-EXPLORATION
(-), I-EXPLORATION
urocultivo I-EXPLORATION
(-) I-EXPLORATION
y I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
leucocitosis I-EXPLORATION
en I-EXPLORATION
mediciones I-EXPLORATION
seriadas. I-EXPLORATION
TAC I-EXPLORATION
tórax I-EXPLORATION
no I-EXPLORATION
presentaba I-EXPLORATION
focos I-EXPLORATION
de I-EXPLORATION
condensación I-EXPLORATION
ni I-EXPLORATION
derrame I-EXPLORATION
pleural I-EXPLORATION
asociado. I-EXPLORATION
<EOS> I-EXPLORATION
Evolucionó B-EVOLUTION
con I-EVOLUTION
rápida I-EVOLUTION
remisión I-EVOLUTION
de I-EVOLUTION
todos I-EVOLUTION
los I-EVOLUTION
síntomas I-EVOLUTION
y I-EVOLUTION
en I-EVOLUTION
menos I-EVOLUTION
de I-EVOLUTION
48 I-EVOLUTION
h I-EVOLUTION
se I-EVOLUTION
trasladó I-EVOLUTION
a I-EVOLUTION
unidad I-EVOLUTION
de I-EVOLUTION
menor I-EVOLUTION
complejidad. I-EVOLUTION
<EOS> I-EVOLUTION

Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
62 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
HTA, I-PAST_MEDICAL_HISTORY
diabetes I-PAST_MEDICAL_HISTORY
mellitus I-PAST_MEDICAL_HISTORY
tipo I-PAST_MEDICAL_HISTORY
2 I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
EPOC I-PAST_MEDICAL_HISTORY
secundario I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
tabaquismo, I-PAST_MEDICAL_HISTORY
consultó B-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
su I-PRESENT_ILLNESS
hospital I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
origen I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
dos I-PRESENT_ILLNESS
días I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
abdominal I-PRESENT_ILLNESS
intenso I-PRESENT_ILLNESS
asociado I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
vómitos. I-PRESENT_ILLNESS
Se B-EXPLORATION
realizó I-EXPLORATION
un I-EXPLORATION
estudio I-EXPLORATION
ecográfico I-EXPLORATION
y I-EXPLORATION
tomografía I-EXPLORATION
computada I-EXPLORATION
(TC) I-EXPLORATION
que I-EXPLORATION
visualizó I-EXPLORATION
un I-EXPLORATION
aneurisma I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
aorta I-EXPLORATION
abdominal I-EXPLORATION
(diámetro I-EXPLORATION
de I-EXPLORATION
5, I-EXPLORATION
6 I-EXPLORATION
cm) I-EXPLORATION
y I-EXPLORATION
una I-EXPLORATION
UPAA I-EXPLORATION
no I-EXPLORATION
complicada, I-EXPLORATION
por I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
derivó I-EXPLORATION
a I-EXPLORATION
nuestro I-EXPLORATION
hospital. I-EXPLORATION
<EOS> I-EXPLORATION
Ingresó I-EXPLORATION
a I-EXPLORATION
nuestro I-EXPLORATION
centro I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
descartó I-EXPLORATION
que I-EXPLORATION
el I-EXPLORATION
dolor I-EXPLORATION
fuera I-EXPLORATION
secundario I-EXPLORATION
a I-EXPLORATION
una I-EXPLORATION
complicación I-EXPLORATION
del I-EXPLORATION
aneurisma I-EXPLORATION
abdominal, I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
ecografía I-EXPLORATION
abdominal I-EXPLORATION
que I-EXPLORATION
sugirió I-EXPLORATION
proceso I-EXPLORATION
infeccioso I-EXPLORATION
en I-EXPLORATION
fosa I-EXPLORATION
iliaca I-EXPLORATION
derecha. I-EXPLORATION
Con I-EXPLORATION
los I-EXPLORATION
antecedentes I-EXPLORATION
reunidos, I-EXPLORATION
se I-EXPLORATION
catalogó I-EXPLORATION
como I-EXPLORATION
abdomen I-EXPLORATION
agudo I-EXPLORATION
apendicular I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
laparotomía I-EXPLORATION
exploradora I-EXPLORATION
encontrándose I-EXPLORATION
tiflitis I-EXPLORATION
y I-EXPLORATION
necrosis I-EXPLORATION
intestinal, I-EXPLORATION
por B-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
efectuar I-TREATMENT
una I-TREATMENT
resección I-TREATMENT
e I-TREATMENT
íleo-ascendo-anastomosis. I-TREATMENT
<EOS> I-TREATMENT
Posteriormente, B-EXPLORATION
debido I-EXPLORATION
al I-EXPLORATION
tiempo I-EXPLORATION
transcurrido, I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
nuevo I-EXPLORATION
Angio-TC I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
UPAA, I-EXPLORATION
con I-EXPLORATION
paso I-EXPLORATION
de I-EXPLORATION
contraste I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
extendía I-EXPLORATION
más I-EXPLORATION
allá I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
pared I-EXPLORATION
aórtica, I-EXPLORATION
sin I-EXPLORATION
clínica I-EXPLORATION
de I-EXPLORATION
SAA. I-EXPLORATION
Se I-EXPLORATION
efectuó I-EXPLORATION
estudio I-EXPLORATION
preoperatorio I-EXPLORATION
con I-EXPLORATION
coronariografía I-EXPLORATION
que I-EXPLORATION
no I-EXPLORATION
mostró I-EXPLORATION
lesiones I-EXPLORATION
significativas I-EXPLORATION
y I-EXPLORATION
ecocardiografía I-EXPLORATION
que I-EXPLORATION
demostró I-EXPLORATION
hipertrofia I-EXPLORATION
ventricular I-EXPLORATION
izquierda, I-EXPLORATION
disfunción I-EXPLORATION
diastólica I-EXPLORATION
tipo I-EXPLORATION
II I-EXPLORATION
y I-EXPLORATION
dilatación I-EXPLORATION
de I-EXPLORATION
aurícula I-EXPLORATION
izquierda. I-EXPLORATION
<EOS> I-EXPLORATION
Debido B-TREATMENT
al I-TREATMENT
alto I-TREATMENT
riesgo I-TREATMENT
que I-TREATMENT
representaba I-TREATMENT
la I-TREATMENT
UPAA, I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
cirugía, I-TREATMENT
que I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
5 I-TREATMENT
semanas I-TREATMENT
posterior I-TREATMENT
a I-TREATMENT
la I-TREATMENT
cirugía I-TREATMENT
abdominal. I-TREATMENT
Se I-TREATMENT
abordó I-TREATMENT
por I-TREATMENT
esternotomía I-TREATMENT
y I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
bajo I-TREATMENT
CEC I-TREATMENT
reemplazo I-TREATMENT
con I-TREATMENT
prótesis I-TREATMENT
de I-TREATMENT
dacron I-TREATMENT
Gelware™#26. I-TREATMENT
Se I-TREATMENT
observó I-TREATMENT
en I-TREATMENT
el I-TREATMENT
intraoperatorio I-TREATMENT
una I-TREATMENT
lesión I-TREATMENT
pulsátil I-TREATMENT
de I-TREATMENT
alrededor I-TREATMENT
de I-TREATMENT
dos I-TREATMENT
centímetros I-TREATMENT
de I-TREATMENT
diámetro I-TREATMENT
en I-TREATMENT
la I-TREATMENT
cara I-TREATMENT
anterior I-TREATMENT
de I-TREATMENT
la I-TREATMENT
AA I-TREATMENT
y, I-TREATMENT
al I-TREATMENT
diseccionar I-TREATMENT
la I-TREATMENT
AA, I-TREATMENT
se I-TREATMENT
encontraron I-TREATMENT
tres I-TREATMENT
úlceras, I-TREATMENT
una I-TREATMENT
de I-TREATMENT
ellas I-TREATMENT
a I-TREATMENT
un I-TREATMENT
centímetro I-TREATMENT
del I-TREATMENT
ostium I-TREATMENT
coronario I-TREATMENT
derecho I-TREATMENT
y I-TREATMENT
no I-TREATMENT
se I-TREATMENT
observó I-TREATMENT
disección I-TREATMENT
aórtica.. I-TREATMENT
<EOS> I-TREATMENT
La B-EVOLUTION
paciente I-EVOLUTION
evolucionó I-EVOLUTION
favorablemente I-EVOLUTION
y I-EVOLUTION
se I-EVOLUTION
dio I-EVOLUTION
de I-EVOLUTION
alta I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
siete I-EVOLUTION
días I-EVOLUTION
postoperada I-EVOLUTION
difiriéndose I-EVOLUTION
la I-EVOLUTION
resolución I-EVOLUTION
del I-EVOLUTION
aneurisma I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
aorta I-EVOLUTION
abdominal. I-EVOLUTION
<EOS> I-EVOLUTION
El B-EXPLORATION
estudio I-EXPLORATION
anatomopatológico I-EXPLORATION
confirmó I-EXPLORATION
UPAA. I-EXPLORATION
Actualmente, B-EVOLUTION
a I-EVOLUTION
un I-EVOLUTION
año I-EVOLUTION
y I-EVOLUTION
diez I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
seguimiento, I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
continúa I-EVOLUTION
sus I-EVOLUTION
controles I-EVOLUTION
en I-EVOLUTION
Cardiología I-EVOLUTION
sin I-EVOLUTION
presentar I-EVOLUTION
sintomatología I-EVOLUTION
cardiovascular. I-EVOLUTION
<EOS> I-EVOLUTION